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Histone deacetylase inhibitors (HDACi) have shown great promise as cancer therapeutics 
through their ability to arrest proliferation in many transformed cell lines through cell cycle 
arrest, apoptosis, cellular differentiation, and inhibition of angiogenesis and cell migration.  
Moreover, as HDACs regulate many essential cellular processes, not only through epigenetic 
control, but also through non-epigenetic protein deacetylation, design of novel HDACi has 
become a popular research avenue in recent years.  Upregulation of HDAC isoforms has been 
observed in many cancer types and it is known that HDACs contribute to cancer survival through 
epigenetic silencing of tumor suppressor genes and deacetylation of tumor suppressor proteins.  
The FDA approval of SAHA and FK-228, two HDACi indicated for use in cutaneous T cell 
lymphoma (CTCL), has further stimulated the pursuit of effective HDACi-based therapies.  
However, several drawbacks have limited HDACi efficacy and broader use in cancer therapy.  
First, most small molecule HDACi suffer from low oral bioavailability and few are targeted to 
particular cell or tissue types.  More importantly, most HDACi are non-selective “pan-inhibitors” 
of several HDAC isoforms, leading to a reduction in overall in vivo potency and debilitating side 
effects.  The greatest overall impediment to broad HDACi validation is the lack of demonstrated 
clinical efficacy in treating solid tumors.  In this thesis, I document the discovery and biological 
activities of three novel classes of HDACi with enhanced potency and pharmacokinetic 
advantages that could address many of the shortcomings of current HDACi agents. 
Nearly all HDACi derive their inhibition activities from concurrent zinc chelation in the 
HDAC active site and interaction with residues on the exterior of the enzyme.  Moreover, the 
surface recognition cap groups of most HDACi are linked without preference to hydrogen bond 
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accepting or donating groups, such as keto and amide groups.  We reasoned that substituting 
these groups with an appropriate, more pharmacokinetically-desirable moiety could improve 
activity if the replacement were a functional isostere.  Replacement of these groups with a 
triazole ring yielded novel aryltriazolylhydroxamate HDACi that have enhanced potency against 
nuclear HDACs and low micromolar anticancer activities. 
Two of the challenges facing current HDACi agents, as mentioned above, are a lack of 
specific targeting and compromised efficacy against solid tumors.  One mode of addressing these 
drawbacks is through a designed multiple ligand capable of inhibiting multiple proliferative 
pathways that also improves the delivery of HDACi to a specific target.  To this end, dual-acting 
inhibitors of Topoisomerase II (Topo II) and HDACi have been designed using the standard 
HDAC and Topo II inhibitors SAHA and Daunorubicin, respectively.  These compounds inhibit 
both HDAC and Topo II, some more potently than the standards.  Significantly, one dual-acting 
compound has sub-micromolar anticancer activity and is delivered in high concentrations 
intracellularly to the perinuclear region. 
Continuing with the theme of targeted HDACi delivery, the need for lung-targeted cancer 
therapies is underscored by the high incidence and mortality associated with cancers of the lung.  
The macrolide antibiotics are antibacterial agents that possess exceptional pharmacokinetics, 
specifically lung delivery and significant lung residence.  In an attempt to harness the 
outstanding properties of macrolides for a lung cancer therapy, macrocyclic HDACi have been 
generated, incorporating macrolide skeletons of azithromycin and clarithromycin macrolides as 
surface recognition cap groups.  A subset of these compounds potently inhibits HDAC and also 
inhibits lung cancer cell viability in low micromolar concencentrations.  Most importantly, 
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azithromycin-based macrocyclic HDACi display a lung-targeted tissue distribution in vivo that 
indicates the significant potential of these compounds against solid lung tumors.
Chapter 1 
Histone Deacetylase, HDAC Inhibitors, and Cancer Treatment 
 
1.1 Histone Deacetylase 
Control of the integrity and expression of double-stranded DNA is essential for the health 
and survival of all living cells.1  Epigenetic control, regulation of gene expression independent of 
changes to the DNA sequence, is a powerful means of regulating cellular function.2  This process 
is essential in normal development as transcription of certain genes are necessary only in certain 
cell types.3  The main eukaryotic epigenetic mechanisms are DNA methylation and post-
translational modifications of histone proteins, including acetylation, methylation, 
phosphorylation, ubiquitination, ADP-ribosylation, and sumoylation.4-8 
Modification of histones via acetylation is controlled by two opposing enzymes:  histone 
acetyltransferase (HAT) and histone deacetylase (HDAC).9-11  HAT transfers acetyl groups onto 
the ε-NH3 groups of histone lysine residues in a reversible process involving acetyl coenzyme 
A.12  Acetylation neutralizes the charge interaction between the negatively-charged DNA 
backbone and positively-charged histone lysines, resulting in a more relaxed nucleosomal 
structure with accessibility of DNA  to transcription factors.13-15    Conversely, HDAC removes 
acetyl groups from histone lysines, resulting in decreased transcription through inaccessibility of 
nucleosome-associated DNA.10 
Histones were first revealed as substrates for HDAC activity four decades ago in 
1969.16,17  Discovery of non-specific inhibition of HDAC activity by butyrate followed in 1978, 
while Trichostatin A, a fungal antibiotic, was shown to be the first specific inhibitor of HDAC in 
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1990.17-19  Using the cyclic-tetrapeptide Trapoxin, an irreversible HDAC inhibitor (HDACi), the 
first HDAC was purified from cow thymus in 1996.20  This HDAC, termed HDAC1, was 
discovered to be an orthologue of yeast protein Rpd3, which had already been profiled as an 
extensive regulator of transcription.21  This link further encouraged the connection between 
histone acetylation and gene regulation, and led to the theory that HDACs serve as epigenetic 
transcriptional repressors.22 
 
Figure 1-1:  Early HDACi used to profile the link between HDAC, histone acetylation, and 
transcriptional repression. 
  
1.2 HDAC Biology 
To date, the HDAC family of enzymes contains 18 known isoforms organized into 4 
classes: class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), and class IV 
(HDAC11) are zinc metalloenzymes, while class III, referred to as sirtuins, have a different 
mechanism of action, requiring NAD+ for activity.  The group organization is based largely on 
sequence homology to yeast analogues and cellular localization.  Class I is primarily nuclear-
localized, while class II is further divided into class IIa (HDACs 4,5,7, and 8) which is found in 
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both the nucleus and cytoplasm, and class IIb (HDACs 6 and 10) which is primarily cytoplasmic 
and has two active sites.23  HDAC11, the sole member of class IV, is structurally related to both 
class I and II HDACs and is found in both nuclear and cytoplasmic cell fractions.23 
Class I HDACs 1, 2, and 3 have been identified as subunits of nuclear protein complexes 
that function in global transcriptional repression.  Complexes including CoRest,24,25 NuRD,26,27 
and Sin328 contain HDAC1 and HDAC2, which confer deacetylase activity to these corepressors.  
HDAC3 has been identified as part of N-Cor /SMRT repressor complex, which regulate the 
repression of nuclear hormone receptors and other transcriptional repressors.29,30  Conversely, 
HDAC8 has not been identified as a part of a transcriptional repression complex and its 
repression functions are still under investigation. 
By contrast, Class IIa HDACs 4, 5, 7, and 9 localize to the nucleus and cytoplasm and 
their shuttling between the two is regulated by the 14-3-3 proteins which bind to these HDACs at 
conserved N-terminal sites and mediate their localization based on the phosphorylation of key 
residues within the 14-3-3 binding sites on HDACs.31,32  Key signaling pathways regulate the 
phosphorylation of these sites, thereby regulating HDAC activities through nuclear 
translocation.33-35  Importantly, class IIb HDAC6 was identified as a microtubule-associated 
deacetylase, and highlighted a key revelation:  HDACs deacetylate a range of non-histone 
proteins in addition to their classical targets, and perhaps a more appropriate title for these 
enzymes would be “lysine deacetylases”.36,37  HDAC10 was shown to repress transcription and 
interact with HDAC3, but its function is still largely unknown.38  HDAC11, the sole member of 




Structural information of all HDAC enzymes is still elusive.  To date, only HDAC841  
and HDAC342 have been crystallized in full, but several catalytic domains of other HDACs have 
been elucidated and are available in the literature.43-45  In the absence of these structures, the 
crystal structure of histone deacetylase-like protein (HDLP), an Aquifex aolicus HDAC 
homologue with 35.2% overall sequence homology to human HDAC1, has been used to profile 
many HDAC ligands and conceptualize the catalytic core, which has high sequence homology.46  
The structural architectures of the HDLP and HDAC8 active sites are conserved in other class I 
and II HDACs.  In HDLP, the Zn2+ ion is buried in the active site, reached by a 14 Å 
hydrophobic tunnel (Figure 1-2).46  Amino acid residues Pro22, Gly140,  Phe141, His 180, 
Phe198, Leu265, and Tyr297 form the tunnel wall, while Asp168, His170, and Asp258, and 
water molecules coordinate the Zn2+ ion for deacetylation activity.46  HDAC8 is structured 
similarly but with a shallower tunnel of 12 Å (Figure 1-3).47   
 
 
Figure 1-2:  Active site (a) and secondary structure (b) of HDLP, a homologue of human 






Figure 1-3:  Active site and secondary structure of human HDAC8. The zinc ion is presented 
as spheres.  Viewed with Pymol.  PDB = 1T69.  
 
The accepted mechanism of deacetylase action on acetylated lysines by HDAC enzymes 
was proposed based on the binding contacts made by the HDAC inhibitors TSA and SAHA on 
HDLP.46  It is thought that the zinc ion binds the carbonyl oxygen of the N-acetyl amide, 
activating the acetylated lysine and orienting the carbonyl carbon close to an activated water 
molecule (Figure 1-4).  The water molecule then attacks, resulting in formation of a tetrahedral 
intermediate with the carbonyl carbon.  Finally, the carbon-nitrogen bond breaks and nitrogen 
accepts a proton from a histidine residue, producing lysine and acetate.  This mechanism is 
supported by studies reporting a complete loss of both deacetylase activity and subsequent 


































































































1.3 Histone Deacetylases and Cancer 
It is now known that HDACs contribute to cancer progression in a variety of ways.  
Dysregulation of the acetylation status of histones has been linked with transcriptional silencing 
of key suppressors of tumorigenesis.  Specifically, HDACs have been shown to be recruited by 
oncoproteins in several cancers in order to aberrantly repress transcription.49-52  Moreover, 
several knockdown experiments have demonstrated the necessity of HDAC expression in 
cancers.  HDACs 1 and 2 have redundant function in cancer, and deletion of both is required to 
halt tumor growth completely.53  Similarly, knockdown of HDAC 1 and 3 is sufficient to inhibit 
proliferation in HeLa cells,54 and siRNA knockdown of HDAC1 causes cell cycle arrest, inhibit 
cell growth, and lead to increased numbers of apoptotic cells, while overexpression of HDAC1 
led to a proliferative phenotype in cultured prostate cells.55,56  HDAC2 knockdown has also 
demonstrated an antiproliferative effect with increased p21waf1-associated apoptosis in cervical 
cancer cells, as well as increases in p53-induced antiproliferative and cell senescence effects in 
breast cancer.57,58  Similarly, separate knockdowns of class I HDACs 3 and 8 caused apoptosis 
and a restoration of gene expression.59,60  By contrast, the cancer-specific contributions of class II 
and IV HDACs are less clear, although HDAC6 is a notable exception with pro-angiogenic and 
prometastatic activities through binding to hypoxia inducible factors (HIFs) and vascular 
endothelial growth factors, respectively.  Overall, the overexpression of many HDAC isoforms 
are associated with specific cancers, and the potent proliferative effects seen by dysregulation of 






1.4 HDAC Inhibition 
1.4.1  HDAC Inhibitors 
To date, a diverse range of natural product and synthetic HDACi have been discovered 
and profiled.  In spite of the significant structural diversity among HDACi, they generally 
conform to a three-motif pharmacophoric model containing a surface recognition cap group, a 
linker chain, and a zinc binding group (ZBG) (Figure 1-5).  The accepted mode of inhibition 
involves the ZBG interacting with the catalytic zinc ion in the active channel, while the linker 
efficiently positions the cap group to make interactions with amino acid residues on the surface 
of the enzyme (Figure 1-6).46   
Selected identified classes of HDACi include short chain fatty acids(butyrate and 
valproic acid), linear hydroxamic acids (SAHA and TSA), benzamides (MS-275), and cyclic 
peptides (FK-228 and CHAPs).  Potencies against HDAC vary by class with activities in the 
millimolar range (fatty acids, micromolar range (benzamides), nanomolar range (linear 
hydroxamates and FK-228), and picomolar (CHAPs).61  Most currently reported HDACi inhibit 
HDAC by liganding the zinc ion and preventing substrate entry into the active site.  Specific 
interactions with the enzyme surface residues correlate well with potency and are thought to be 
essential for activity towards individual isoforms.  This is an attractive pursuit due to the fact that 
certain cancers only upregulate distinct HDAC isoforms,23 and since most HDACi so far 
discovered are non-selective “pan inhibitors” of many isoforms, better efficacy might be 
achieved with a more selective inhibitor.  In addition, more selective inhibitors could be used to 
further probe the activities and functions of specific HDAC isoforms, as well as assist in 





















Suberoylanilide Hydroxamic Acid (SAHA)  





Figure 1-6:  Crystal structure of SAHA (blue) bound to HDLP (gray).  Consistent with the 
accepted mode of inhibition, the hydroxamic acid binds the zinc ion (red), the linker fills the 
active site channel, and the surface recognition group interacts with surface residues on the 
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1.4.2 In Vitro HDAC Inhibition 
For the past 15 years, HDAC inhibition has been a prominent and rapidly expanding 
research avenue.  HDAC inhibitors (HDACi) have demonstrated great potential as in vitro 
anticancer agents through their ability to arrest the growth of nearly all transformed cell types, 
initiate differentiation, promote apoptosis, and inhibit angiogenesis.62-64  Treatment of cultured 
cancer cells with HDACi results in cell cycle arrest at G1 and, occasionally, G2 checkpoints at 
concentrations of drug that also cause accumulation of acetylated histones.62  Histones become 
acetylated in response to HDACi in both normal and cancerous cells, with acetylation of H2A, 
H2B, H3, and H4 commonly observed.65  Importantly, HDACi-induced toxicity is cancer-
specific, as doses that are toxic to transformed cells cause no apoptosis in normal cell lines.66 
One of the main intracellular effects observed with HDACi treatment, is increase in the 
expression of p21waf1, a cyclin dependent kinase inhibitor.67,68  p21 is a regulator of the cell cycle 
through its inhibition activity and causes cell cycle arrest at G1.  SAHA treatment specifically 
causes increases in acetylated histones associated with the p21 gene promoter.67  Likewise, many 
of the gene targets that are upregulated with HDACi treatment have been identified as 
antiproliferative proteins.69a  This has led to the theory that recruitment of HDACs and 
subsequent transcriptional dysregulation, specifically of tumor suppressor genes, could be a 
common modality for initiation of proliferation.  Of great significance is the discovery that 
HDACs have a diverse range of non-histone substrates, many of which are attractive cancer 
targets themselves, such as p5369b, E2F69c/d, tubulin37, and Hsp9069e.  This revelation greatly 
broadened the scope by which these inhibitors were thought to exert their activities and further 
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underscores the promising anticancer activities that could be possible through the appropriate 
modification of HDACi molecules. 
 
1.4.3 HDAC Inhibition in Animal Models 
Several HDACi inhibit in vivo tumor growth when adiministered intravenously or 
intraperitoneally in a variety of animal cancer models, including lung, breast, prostate, and 
leukemia models, with little toxicity.22,62,70  Treatment with HDAC inhibitors results in 
acetylated histones in tumor tissues and normal tissues, such as the spleen and liver,71 but it 
should be noted that increased amounts of acetylated histones in normal cells are not correlated 
with growth inhibition.62   
One animal model for human prostate cancer showed remarkable susceptibility to 
SAHA-induced cytotoxicity.62  CWR22 human prostate xenografts that were dosed with 25, 50, 
and 100 mg/kg/day with SAHA were reduced by 78%, 97%, and 97% tumor volume, 
respectively, compared to vehicle-treated control animals.  The most effective dosing 
concentration was determined to be 50 mg/kg, as the lower dose showed less tumor regression 
and the higher dose had equivalent activity, but with evidence of toxicity.62  Moreover, both the 
25 mg/kg/day and 50 mg/kg/day treatment groups were tested for HDAC activity in the CWR22 
tumors.  Both groups showed significant increases in acetylated histones H3 and H4 at 6 hours 
post-treatment.  These levels fell, however, with only the 50 mg/kg/day dose causing noticeable 
histone acetylation after 12 hours.  The encouraging in vivo anticancer data shown against this 
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mouse tumor model provided the basis for human testing in clinical trials that followed shortly 
after. 
 
1.5 Clinical Successes with HDAC Inhibitors 
1.5.1 SAHA 
SAHA was initially investigated in a Phase I intravenous dosing study.73  Two treatment 
cohorts were tested.  The first started patients on doses ranging from 75 to 900 mg/m2/day for 3 
consecutive days, 21 days apart.  The second cohort started patients on infusions of 300 
mg/m2/day for 5 consecutive days on 3 consecutive weeks and then the dose was increased to 
either 600 or 900 mg/m2/day.  37 patients were treated with 25 having solid tumors and 12 with 
hematological malignancies.  Patients with solid tumors were placed on higher dosage cohorts 
and were safely administered doses of SAHA 3 times higher than patients with hematological 
malignancies. 
From this study, 2 patients with refractory bladder cancer had reductions in pelvic tumor 
masses and improvements in tumor-related pain.  However, once these patients were taken off of 
the treatment regimen, their disease progressed within 2 months.  Two patients with refractory 
Hodgkin’s lymphoma also responded to treatment with SAHA.  The first patient was dosed with 
the 600 mg/m2 concentration and showed 30% reduction in her lung lesions, before she had to 
discontinue treatment due to a secondary infection, after which her disease again progressed.  
The second patient on the 300 mg/m2 dose demonstrated a stable disease phenotype through CT 
and PET scans and was maintained on the treatment regimen for 8 months, during which time 
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she was able to return to work.  She later converted to an oral SAHA treatment for ease of 
administration, as it became available after the Phase I trial was concluded. 
Significantly, 1 patient had an acute myocardial infarction and died while on the 
treatment regimen.  He was a life-long cigarette smoker and an autopsy could not determine a 
reasonable link between his cardiac event and SAHA treatment.  However, this event, coupled 
with irregularities in cardiac nerve repolarization (QTc elongation) that have been observed in all 
HDACi clinical trials, created initial concern for heart-related cytotoxicity.  Electrocardiogram 
monitoring of patients was subsequently performed before, during, and after treatment with 
SAHA. 
Histone acetylation was investigated via blood samples in patients with hematological 
malignancies.  Lower doses of SAHA did not cause observable histone acetylation when blood 
was assayed 2 hours post-treatment.  Higher doses of SAHA caused accumulation of acetylated 
histones for at least 4 hours post-treatment.  This result was underscored by the short half-life of 
SAHA (0.35-1.3 hours) when administered intravenously.  Solid tumors that were biopsied and 
tested for acetylated histones were positive for acetylated histones in 60% of the patients tested. 
Subsequently, an oral formulation of SAHA became available and was assayed by a 
Phase I trial in patients with advanced-stage cancers.74  73 patients were tested and dose-limiting 
toxicities were effects also common to the previous study:  anorexia, dehydration, diarrhea, and 
fatigue.  Maximum tolerated doses of 400 mg/day, or alternatively, 200 mg taken twice daily for 
continuous dosing.  300 mg taken twice daily could be tolerated on a 3 day/week regimen.  Oral 
SAHA was shown to have 43% bioavailability with peak plasma concentrations between 2 and 3 
hours.  Half-lives were dose-dependent and were improved by fasting the patient.  The resulting 
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half lives were between 1.5 and 2 hours, depending on the dose.  This study resulted in 1 
complete response, 3 partial responses, and 2 unconfirmed partial responses.  Moreover, SAHA 
was well tolerated and 22 patients remained on the treatment for between 4 and 37 months.  
Common side effects included nausea, vomiting, diarrhea, and dehydration.  More serious side 
effects, specifically neutropenia (decrease in blood neutrophils) and thrombocytopenia 
(decreased platelets) were observed uncommonly.  Oral SAHA also caused accumulation of 
acetylated histone, more commonly observed at higher doses of drug. 
A phase II trial of oral SAHA centered on treating patients with refractory cutaneous T-
cell lymphoma.75  This study tested doses of 400 mg/day, 300 mg twice daily for 3 consecutive 
days, or 300 mg/day for 14 consecutive days followed by 7 days rest.  The primary objective 
focused on determining the clinical response to oral SAHA.  33 patients were enrolled and all 
had received previous therapies for CTCL.  The 400 mg/day regimen demonstrated the highest 
safety profile.  Adverse effects included nausea and fatigue with more serious thrombocytopenia 
rarely observed.  There were no complete responses, but 8 patients showed partial responses to 
treatment, of which 1 had early-stage disease and 7 had more progressive CTCL.  The cancer 
response rate to oral SAHA was determined to be 24%, while 58% received some sort of clinical 
benefit, such as decreased inflammation or pain relief.  Significantly, tested CTCL lesions 
demonstrated apoptosis of malignant T-cells, a cell cycle arrest at the G2 checkpoint, and higher 
levels of p21waf1 expression.   
Overall, these  clinical trials demonstrated the anticancer action of SAHA in vivo.  
Consistent with the accepted mechanism of HDAC inhibition, SAHA caused acetylation of 
histones in many patients and achieved moderate efficacy against CTCL.  However, acetylated 
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histones were only seen with higher doses of SAHA and even then, acetylated histones were not 
observed in all tumors.  Based on the clinical successes, SAHA was approved for the treatment 
of CTCL in 2006, however, the low half-life and limited efficacy against solid tumors are both 
serious obstacles to broad use. 
1.5.2 FK-228 
To date, FK-228 (Romidepsin) is the only macrocyclic HDACi to progress through 
clinical trials.  FK-228 was initially assessed for responses against a range of solid tumors, and 
results from these studies showed promising responses among tested patients.76  Initially two 
Phase I dosing trials were carried out.  The first trial incorporated two doses at days 1 and 5, 
repeating every three weeks, while the second trial administered three doses on days 1, 8, and 15, 
repeating every four weeks.  The maximum tolerated dose for each study was determined to be 
17.8 mg/m2 and 14 mg/m2, respectively.  Most patients showed limited activity, although 
promising responses against cutaneous T-cell lymphoma (CTCL) were observed.76  It should be 
noted that in an additional cohort, included after completion of the first trial, a patient with 
peripheral T-cell lymphoma experienced complete remission in response to FK-228.  Following 
this success and similar results obtained in patients with cutaneous T-cell lymphomas, a Phase II 
trial was launched with a recommended dose of 17.8 mg/m2, administered on days 1 and 5 of a 
21 day rotation.77 
While responses against CTCL were promising, none of the patients experienced a 
complete remission.77  Because of this, other Phase II trials were initiated with the focus on 
combination therapies of FK-228 and cytotoxic anticancer agents such as the proteasome 
inhibitor bortezomib and the nucleoside analogue gemcitabine.78,79  Additionally, a Phase II trial 
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involving FK-228 as a single agent against previously-treated colorectal cancer was completed, 
but no objective responses were observed.80 
Since the publication of the initial clinical results, FK-228 has entered numerous clinical 
trials against other forms of cancer, including lung cancer and various types of leukemia.81,82  In 
trials against acute myeloid leukemia (AML), apoptosis has been observed at concentrations that 
suggest HDAC inhibition as a mechanism.81  After completion of that study, several patients 
showed measurable antitumor responses, but no complete responses were observed.80  
Contrasting with this result, another clinical trial using FK-228 against AML showed no 
significant change in chromatin acetylation, specifically on histone H3 and H4, but did result in 
one complete remission and six stable disease conditions.83  In a trial against lung cancer, FK-
228 produced no objective responses, but did confirm in vitro findings, namely resulting in 
histone H4 acetylation, p21 expression, and a general shift in gene expression towards  normal 
lung epithelia.82 
There has been some concern over preclinical data that suggests that FK-228 could result 
in cardiac toxicity.  One trial reported serious cardiac complications in tested participants and 
had to be terminated due to the death of one patient.84  The cause of death could not be 
determined, but was assumed to be due to a ventricular arrhythmia that may have been related to 
several other factor, FK-228 treatment being one.  On the basis of this, the trial was terminated.  
Also two patients were observed with asymptomatic ventricular tachycardia and three experience 
QTc prolongations, but these resolved between doses.  It should be noted that the results of this 
trial contrast greatly with subsequent clinical results.  To date, no other clinical observations of 
significant cardiac toxicity have been reported in studies using FK-228 however it is important to 
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underscore that the serious adverse cardiac effects seen with FK-228 treatment could be cause 
for concern. 80,82,83,85,86  With the exception to this mar, Fk-228 has shown great promise in the 
clinic, specifically against T-cell lymphoma.  Of particular note is the remarkable length of 
response to FK-228, even after treatment has ceased, extending over 3 years in some cases.87 
Due to the successes of these clinical trials, FK-228 (Istodax) was approved by the FDA for 
treatment of CTCL.88  However, the cardiac-related death, in conjunction with a similar event in 
the SAHA clinical trials and cardiac effects common to HDACi, have created concerns over the 
safety and cardiotoxicity of HDACi.  Moreover, in spite of promising clinical results by SAHA 
and FK-228, clinical efficacy against solid tumors has remained a significant challenge.  In order 
to further HDACi-based therapies, these issue will need to be addressed. 
 
1.6 Current Strategies to Increase the Efficacy of HDACi 
In spite of the successes of SAHA (Vorinostat) and FK-228 (Istodax) against CTCL, 
several challenges remain to HDACi-based cancer chemotherapeutics.  First, concerns over 
dose-limiting cardiotoxicity have created the perception that HDACi use is plagued by serious 
side effects.  This has only been exacerbated by the lack of clinical efficacy shown against solid 
tumors.89,90  No patient to date has experienced a complete or even a partial response of a solid 
tumor with HDACi therapy.  The prevalence of dose-limiting side effects such as fatigue, 
anorexia, diarrhea, or more serious hematological and cardiac adverse effects like 
thrombocytopenia and QTc prolongation, respectively, further limit the broad applicability of 
these compounds.  Overcoming these challenges will require innovation, both in terms of the 
design of new agents, as well as strategies to increase their efficacy and limit off-target toxicity. 
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1.6.1  Localized Administration 
One strategy that is currently being pursued to limit toxicity and more specifically deliver 
HDACi is local administration to cancerous tissue.  Localizing HDACi has been achieved 
through surgically-placed biodegradable polymers, intratumoral injection, and topical 
application.91-93  Specifically, topical FK-228 administration to skin lesions on patients with 
CTCL achieved selective delivery with low systemic side effects.94  Topical administration of 
other HDACi have shown promising results in phase II trials against non-melanoma skin cancer 
with complete or near complete remission in 75% of patients treated and partial responses in the 
remaining, with only mild inflammatory side effects.92  Local administration of HDACi, while 
promising in these studies, is not a viable strategy for most tumors, but it does demonstrate the 
potential that localized delivery of HDACi could have for improving efficacy and reducing the 
side effects common to clinical HDACi trials. 
1.6.2 Targeted HDAC Inhibitors 
Selective biological targeting of HDACi could address many of the shortcomings of 
current inhibitors.  Targeted delivery of anticancer agents is a proven strategy for increasing 
efficacy by selectively accumulating chemotherapeutics to the target of interest, while limiting 
side effects brought about by off-target interactions.95-98  Specific targeting of HDACi through 
moieties that also function to selectively deliver or target the HDACi to distinct tissues or cell 
types could confer interesting and beneficial effects on current agents.  Because the HDAC 
enzyme surface is relatively tolerant of a diverse range of HDACi cap groups99, modification of 
this moiety could be a viable strategy for introducing targeting groups to confer better specificity 
to HDACi.  Targeting this new generation of HDACi to specific tissues or cell types has the 
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potential for vastly decreasing the side effects currently associated with HDACi, while also 
conferring greater efficacy by concentrating more drug in target sites.  This could allow for a 
lower therapeutic dose, further minimizing side effects.  The HDACi surface recognition cap 
group, which is the most substitution-tolerant moiety of the HDACi pharmacophore, could be 
modified to incorporate appropriate groups that would not only interact favorably with HDAC 
residues, but also target the inhibitor specifically to certain cell types in the body.  By combining 
targeting and inhibition capabilities within a single agent, it is possible that this type of integrated 
HDACi could improve the therapeutic profile by reducing off-target side effects and 
accumulating in solid tumors. 
On the other hand, targeting HDAC as part of a designed multiple ligand could confer the 
broad anticancer effects concomitant with HDACi along with potent chemotoxic effects inherent 
to other anticancer agents.  A dual targeted agent of this type could broadly arrest cancer 
proliferation through multiple pathways, achieving greater efficacy than a highly selective 
inhibitor.  Moreover, nucleosomal relaxation conferred by inhibition of nuclear HDACs could be 
used to potentiate DNA-binding anticancer agents.100  The association of nuclear HDACs with 
Topoisomerase II (Topo II) in vivo101 offers a unique opportunity to harness the potent activity of 
anthracyclines and the broad effects of HDACi in a single, multi-targeted drug. 
Both of these approaches represent novel targeted HDACi-based strategies aimed at 
overcoming the clinical inefficacy of HDACi and creating more potent, multifunctional drugs.  
To this end, I will document in this thesis the profiling and biological activities of four new 
classes of HDACi.  (1) aryltriazolylhydroxamate HDACi that potently inhibit HDAC activity 
and prostate cancer cell growth, (2) dual-targeted inhibitors of Topoisomerase II and HDAC and 
22 
 
(3) dual-targeted inhibitors of Topoisomerase I and HDAC, both of which have potent inhibition 
against both target enzymes as well as cancer cell lines, and finally (4) macrocyclic HDACi that 
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Linear Aryltriazolyl HDAC Inhibitors 
 
The promise of HDAC inhibitors is due largely to their ability to broadly arrest cancer 
growth of nearly all transformed cell types through mechanisms including cell cycle arrest, 
differentiation, inhibition of angiogenesis, and apoptosis.1,2   Recent validation through the FDA 
approvals of suberoylanilide hydroxamic acid (SAHA) and depsipeptide (FK-228) has 
underscored the promise of HDAC inhibitors as a viable treatment option.3  Both are treatment 
options for cutaneous T-cell lymphoma, a debilitating hematological malignancy.  In spite of the 
success of these HDACi, there are still questions over the viability of HDACi as a treatment 
option, specifically against solid tumors.4  Consequently, much of the current research focuses on 
improving the pharmacokinetic and pharmacodynamic properties of current HDACi.  The 
classical HDACi pharmacophore consists of three structural motifs: a zinc-binding group (ZBG), 
a hydrophobic linker, and a surface recognition cap group (Figure 2-1a).  The ZBG interacts with 
the Zn2+ ion at the base of the active channel5, while the linker group fills the channel, and the 
cap group interacts with surface residues near the rim of the channel.  The most common ZBG 
for HDACi is the hydroxamate group.  Several modifications of the ZBG have yielded other 
modestly successful groups, such as benzamides, α-ketoesters, electrophilic ketones, 
mercaptoamide, and phosphonates.6  Consequently, the cap group has become an attractive 





2.1 Design of Aryltriazolylhydroxamates 
Current HDACi surface recognition groups are linked to the linker group through 
hydrogen bond acceptor and donor groups, such as keto and amide groups (Figure 2-1b).  The 
lack of preference seen in the diversity of these HDACi suggests that more pharmacokinetically/ 
pharmacodynamically desirable and more synthetically tractable groups could be incorporated to 
simplify the molecular design and creation of novel HDACi.  It was proposed that the 1,2,3-
triazole group could be a good candidate for an isostere of the keto and amide linker groups and 
facilitate better inhibition through increased hydrogen bonding.7   
         (a) 
 
         (b) 
 





2.2 In Vitro HDAC Inhibition by SAHA-like Aryltriazolylhydroxamates 
Initial synthesis was carried out using the structure of SAHA as a template in order to 
directly compare the effects of replacement of the amide linker with a triazole group in SAHA-
like aryltriazolylhydroxamates (Table 2-1b).7  In addition to incorporating the triazole group, the 
methylene linker was also varied in order to better assess the optimal linker chain length for 
HDAC inhibition.  The compound panel was assayed for in vitro HDAC inhibition using the 
Fluor de Lys assay, which uses HeLa nuclear extract as a source of HDAC enzymes, specifically 
class I HDACs 1 and 2, in conjunction with a fluorescent acetyl-lysine substrate.  Compound 4a 
had no discernable HDAC inhibition, while 4b-4d showed a linker length-dependent anti-HDAC 
activity.  In order to investigate the effects of triazole ring replacement, inhibition values for 
SAHA were compared to 4c, which most closely approximates the length of SAHA.  This 
revealed a 4.5 fold potentiation in HDAC inhibition compared to SAHA.  Moreover, an 
extension of the linker by one methylene group (4d) further increased the potency over six fold 
compared to SAHA.  Overall, the nanomolar range of inhibition values showed that the triazole 
group is not only a viable attachment option for the linker, but also that the ideal linker length is 










Table 2-1:   In vitro inhibition data for SAHA-like aryltriazolylhydroxamates.  
  
Compound n IC50 (nM)
a
 
4a 1 N.D.b 
4b 2 110.0 
4c 3 14.2 
4d
c
 4 9.6 
SAHA - 65.0 
(a)  Half-maximal inhibition values (IC50) 
were the mean of 3 independent 
experiments using the Fluor de Lys assay.  
(b)  N.D. = nondeterminable. 
(c)  Compound synthesized by Dr. Vishal Patil 
4a-c synthesized by Dr. Bob Chen 
SAHA and was used as a HDACi control. 
 
In order to further interrogate the potential of triazole-based HDACi, a diverse compound 
panel was synthesized to evaluate the structure activity relationship (SAR) inherent to 
substitution of the aromatic the cap group.  Linker lengths of five and six methylenes were used 
following the chain length-dependent inhibition pattern observed in 4a-d.  Introduction of an 
N,N-dimethylamino group, similar to the cap group of TSA (Figure 2-1b), resulted in a five 
methylene-linked compound that was comparable in HDAC inhibition to TSA (5nM IC50) and 
25 fold more active than the corresponding six methylene-linked compound (Table 2-2, 
comparing 7a and 7b).  Conversely, nitrogen substitution within the aromatic ring (7c-f) did not 
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increase HDAC inhibition relative to 4c and 4d, but HDACi activity did vary depending on the 
location of the nitrogen substitution with the 2-pyridyl derivative 7e being the most active.  
Increasing the linker length of the 2-pyridyl derivative further increased the potency (7f vs. 7e), 
similar to the trend observed in 4c and 4d.  Likewise, methyl substitution on the aromatic ring 
lent a preference toward ortho substitution (7g-7i).  Interestingly, this trend is reversed with 
methoxy substitution on the ring, with para-substituted 7j being the most potent and ortho 
substitution the least (7j-l).  It is possible that the para-substituted preference observed is due to 
the increased steric bulk of the methoxy group as this trend has been seen in methoxy 
substitution on SAHA-like HDACi linked through a ketone group.8  Attenuation in activity was 
further observed with the bisortho methoxy-substituted compound 7m, reinforcing the theory 
that methoxy-substituted compounds are sterically constrained. 
Substitution with biphenyl ring systems in compounds 7o-t demonstrates variable anti-
HDAC activity with a 50 fold preference for meta substitution of the biphenyl group over para 
substitution (7o vs. 7p), and ortho substitution resulting in the lowest activity.  Introduction of 
nitrogen potentiated para-biphenyl compounds with 7s having nearly identical activity to 7p, 
while a clear preference for five methylene linkers was observed, regardless of biphenyl 
substitution or attachment. 
Substitution with fused six-six ring systems including naphthalenes and quinolines also 
resulted in potent HDACi activities.  Parallel with the activities of pyridine compounds 7c-e, the 
2-quinoline derivative 7w is more active than 7-quinoline analog 7x, underscoring the selectivity 
for ortho-substitution with aromatic cap groups that contain nitrogen.  The marked preference for 
a five methylene linker in naphthalene compound 7u over the six methylene-linked 7v further 
highlighted the preference for shorter linkers in large cap group compounds. 
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Compound R n IC50 (nM) 
 
Compound R n IC50 (nM) 
7k 
 











3 315.9  SAHA - - 65 
Compounds synthesized by Dr. Bob Chen and Dr. Vishal Patil 
In addition to SAHA, TSA was used as a control, with an IC50 of 5 nM. 
All data represent the mean value of at least three independent experiments using the Fluor de 
Lys assay. 
a N.D., nondeterminable within the tested concentration range (0.5-1000 nM) 
 
Finally, the placement of the triazole ring was shown to be immensely important due to 
the lack of activity of 7y.  Compounds 4c and 7y are isomeric compounds with the same number 
of carbon atoms separating the cap group and hydroxamate.  While 4c is directly attached to the 
triazole ring, the triazole of 7y is displaced toward the hydroxamate by one methylene.  The low 
activity of 7y demonstrates the importance of the positioning of the triazole ring and offers 







2.2.1 Molecular Docking of Aryltriazolylhydroxamate HDACi 
In order to better understand the structural basis of the broad disparity in HDAC 
inhibition values of aryltriazolylhydroxamates, molecular docking was performed using a 
validated docking program (AutoDock).9-11  Compounds were docked with histone deacetylase-
like protein (HDLP), chosen due to its high conservation of active site residues relative to class I 
HDACs.12  In addition, crystal structures for HDLP bound with the HDACi SAHA and TSA are 
available for public use.  All docking experiments were carried out on AutoDock 3.5 to the 
specifications of Lu et al11 and the crystal structures of HDLP bound with SAHA and TSA, two 
known HDACi, are available in the public domain12, aiding in validation. 
SAHA (IC50 = 65 nM), 7o (IC50 = 52 nM), 7p (IC50 = 1.9 nM), and 7u (IC50 = 1.8 nM) 
were all independently docked to HDLP, revealing binding preferences for two different pockets 
on the enzyme surface (Figure 2-2).  Four possible binding pockets have been identified on the 
surface of HDLP to which binding could enhance inhibition.10  Compounds 7o and 7u bind to 
the designated pocket 1, while SAHA and 7p bind to pocket 2.  The 1,4-biphenyl ring of 7o 
adopted a coplanar orientation in its interaction with pocket 1, presumably with the stacking 
interactions of pocket 1 directing toward the co-planar geometry.  This assumption is reinforced 
due to the similar orientation adopted by 7u with its flat, fused six-six ring cap group.  
Conversely, 7p adopted a nonplanar conformation with its 1,3-biphenyl cap group in order to 
bind to pocket 2.  Upon closer inspection, the consequence of 7o adopting the coplanar 
conformation in pocket 1 is that a kink is introduced into the linker chain.  This has the effect of 
extracting the hydroxamate away from the zinc, offering an explanation for the reduced potency 





Figure 2-2:  Molecular docking of aryltriazolylhydroxamates.  SAHA (blue), 7o (orange), 7p 
(green), and 7u (magenta) to HDLP using AutoDock 3.05, viewed with Pymol. (a) surface of 
HDLP near the active site; (b) transverse view of aryltriazolylhydroxamates coordinating 







2.3 Anticancer Activity of Aryltriazolyl HDACi 
To screen for the anticancer activity of the aryltriazolyl HDACi, we tested selected 
compounds against DU-145 prostate cancer cells, a cell line known to respond to HDAC 
inhibition.13  Compounds 7s, 7u, 7v, and 7w were evaluated along with the HDACi standard 
SAHA using both trypan blue exclusion and the MTS assay to qualitatively and quantitatively 
measure the effects of compound exposure for 72 hours on cell viability.14,15  Treatment of DU-
145 cells with SAHA gave an IC50 measurement around 2.1 µM in close agreement with 
literature values reported under similar experimental conditions.16  Compounds 7s, 7u, 7v, and 
7w were selected  as lead compounds based on the potency of their inhibition of in vitro HDAC 
activity (Table 2-2).  All compounds demonstrated low micromolar IC50 values ranging from 2.2 
to 8.0 µM, with 7w inhibiting prostate cancer cell growth at a level near that observed by SAHA.  
Overall, these results demonstrated the suitability of the triazole ring as a linking moiety in 
aryltriazolyl HDACi, a novel class of HDAC inhibitors. 
 
2.4 Conclusion 
These results have demonstrated the suitability of the 1,2,3-triazole ring as a surface 
recognition cap group-linking moiety in SAHA-like aryltriazolyl HDACi.  A preference for five 
or six methylene-linker chains was observed in the SAR of these compounds.  Moreover, several 
compounds have been identified that rival or exceed SAHA’s in vitro HDAC inhibition.  A 
subset of these inhibitors also arrests the growth of DU-145 prostate cancer cells.  It is possible 
that these compounds will also possess enhanced in vivo activity compared with HDACi with 
keto-amide linkages, due to resistance of the triazole to metabolic degradation.17 
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2.3 4.72 3.07 
 
1.8 3.95 2.6 
 
15.3 7.76 3.99 
 
2.1 2.25 2.46 
 
65.0 2.12 2.11 
SAHA was used as a control for all listed values. 
a Cellular IC50 values were determined by trypan blue exclusion. 







2.5 Experimental Procedures 
2.5.1 In Vitro HDAC Inhibition Assay 
All inhibitors were screened for HDAC inhibition using the HDAC Fluorescent Activity 
Assay/Drug Discovery Kit (Fluor de Lys AK-500, Biomol [now Enzo Biosciences]).  All 
compounds were solubilized in DMSO to a stock concentration of 10mM, from which test 
dilutions were made in DMSO.  All kit reagents were stored at -80°C and thawed on ice shortly 
before the experiment.  All experiments were performed in black 96-well microplates.  First, 
compounds were diluted to 10X test concentrations in distilled water, and 5µl of each test 
concentration was added to test wells.  This was then diluted with 5µl of assay buffer (50 mM 
Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) in each well.  Control wells 
received an equal volume of assay buffer.  HeLa extract, as provided, was diluted 30X in assay 
buffer and 15µl was added to all wells.  The fluorogenic substrate was then diluted to 40µM and 
25µl was added to all wells and allowed to incubate at room temperature for 15 minutes.  HDAC 
reactions were stopped with 100µl of a developer/TSA mixture.  Fluorescence was assayed after 
20 minutes at excitation and emission wavelengths of 360 nm and 460 nm, respectively.  In vitro 
IC50 values were calculated using a graph of log(concentration) vs. logit(fluorescence). 
 
2.5.2 Cell Viability Experiments 
Human prostate carcinoma cells (DU-145 were obtained from the American Type 
Culture Collection (Manassas, VA).  Cultures were grown in Eagles Minimal Medium (EMEM) 
containing L-glutamine (5 mM), sodium pyruvate (1 mM), sodium bicarbonate (1500 mg/L), and 
10% fetal bovine serum.  Cell cultures were maintained at 37°C with 5% CO2.  SAHA, and all 
other HDACi tested were dissolved in DMSO at a stock concentration of 10 mM and stored at -
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80°C.  Cells were passaged and allowed to grow for 24 hours prior to the addition of compounds.  
All compounds were diluted to appropriate test concentrations (0.5 – 10 µM) in complete 
medium and added to cultures for a duration of 72 hours.  Viability was assessed by trypan blue 
exclusion as well as by mitochondrial activity via the MTS Assay (Promega). 
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 CHAPTER 3 
Dual Targeted Inhibitors of Topoisomerase and Histone Deacetylase 
Several rational pharmacological strategies, including vaccination, gene therapy, 
immunotherapy, and new target identification and validation, have emerged for the treatment of 
metastatic diseases.  In spite of this progress, chemotherapy remains the primary treatment 
option of choice for most cases of cancer.  However, nearly all chemotherapeutic agents suffer 
from severe toxicities, as well as a range of undesirable side effects.  To address these problems, 
the cancer treatment of the future will incorporate, within a single molecule, elements that allow 
for simultaneous targeting of multiple therapeutic targets, while maintaining lower side effects.1-3  
This realization has continued to spawn immense efforts in the literature.  Studies directed 
toward identifying multivalent ligands that are promising pharmacological agents that may be 
more efficacious for various human diseases than highly selective single-target drugs are 
ongoing in several academic and pharmaceutical laboratories.4-7  A subset of these studies has 
revealed that balanced modulation of a small number of targets may have superior efficacy and 
fewer side effects than single-target treatments.1,7,8 
Epigenetic control has become widely accepted as a mechanism for cellular regulation.9-
11  Specifically, HDAC enzymes have generated much interest in cancer therapeutic literature 
because of their known associations with many oncogenes and tumor suppressors, leading to 
altered expression patterns, and have consequently become attractive targets for small-molecule 
inhibition.12,13  HDACi have been shown to cause growth arrest, differentiation, and apoptosis in 
tumor cells and in animal models by inducing histone hyperacetylation and p21waf1 expression.14-
17  Additionally, modulation of activities of HDACs alters the activity of a diverse range of 
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proteins, many of which are attractive therapeutic targets themselves, including p53, E2F, 
tubulin, and Hsp90.18-22  HDAC inhibition has been clinically validated as a therapeutic strategy 
for cancer treatment with the FDA approvals of vorinostat (SAHA) and romidepsin (FK-228) for 
the treatment of cutaneous T-cell lymphoma.23-25  However, a large number of the currently 
known HDACi have elicited only limited in vivo antitumor activities and have not progressed 
beyond preclinical characterizations.26-28  HDACi that modulate the functions of additional 
intracellular targets, other than the various HDAC isoforms, may be able to ameliorate many of 
the shortcomings of current inhibitors. 
 
3.1 Design of Dual-Targeted Topo II-HDAC Inhibitors 
Because of the presence of large hydrophobic patches at the HDAC surface rim,29,30 it is 
conceivable that appropriate conjugation of the surface recognition group of a prototypical 
HDACi to other hydrophobic antitumor pharmacophores could furnish a new class of 
bifunctional agents.  To date, there exist only a few examples of this subtype of bifunctional 
HDACi-derived compounds.31-33  Expansion of the repertoire of such bifunctional compounds 
could lead to broad acting, therapeutically viable anticancer agents. 
An attractive starting point for the secondary target is the topoisomerase class of enzymes 
(Topo I and Topo II), which are validated targets for many small molecule inhibitors including 
clinically useful anthracyclines such as doxorubicin (DOX) and daunorubicin (DAU) (Figure 3-
1) and camptothecins such as irinotecan and topotecan.34  Topo inhibitors elicit anticancer 
activities primarily by stabilizing the DNA-enzyme cleavable complex through intercalation 
between DNA base pairs.  However, DNA does not exist as a naked structure in the nucleus.  It 
is noncovalently associated with histones to form the nucleosomes which make up chromatin 
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subunits.  Agents, such as HDACi, that induce hyperacetylation of histone proteins complexed 
with DNA could increase the accessibility of DNA within chromatin and consequently potentiate 
the anticancer activities of Topo inhibitors.35,36  Moreover, recent observations have shown that 
HDAC1, HDAC2, and Topo II colocalize in vivo as part of functionally-coupled complexes.37,38  
This evidence suggests that simultaneous Topo and HDAC inhibition could be a viable 
alternative approach in cancer therapy. 
The following chapter will discuss the design and biological characterization of novel 
small molecules with dual-acting Topo II-HDAC inhibitory activities.  Many of these conjugates 
inhibit HDAC and Topo II activities more potently than SAHA and daunorubicin, standard 
HDACi and Topo II inhibitors, respectively.  Additionally, a subset of these compounds 
exhibited potent whole cell antiproliferative activities against representative breast, lung, and 
prostate cell lines. [Dr. William Guerrant, Dr. Vishal Patil, and Josh Canzoneri contributed to 
this work equally.] 
 
 
Figure 3-1: Representative structures of anthracyclines. 
 
Anthracyclines are one of the most thoroughly studied classes of anticancer agents, with 
copious structure-activity relationship (SAR) data to aid in the design and characterization of 
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new anthracycline-containing compounds.39-44  Specifically, N-benzylated anthracyclines, such 
as N-benzyl doxorubicin (AD-288)42 (Figure 3-1), have enhanced Topo II inhibition activities, 
reduced cardiotoxicity, and reduced susceptibility to Pgp-mediated multidrug resistance.45-47  We 
postulated that introduction of the HDACi through N-benzylation of the daunosamine sugar of 
DAU would be compatible with Topo II inhibition while possibly engendering the favorable 
attributes of N-benzylated anthracyclines to the resulting conjugates.  In turn, the anthracycline 
moiety could serve two other purposes:  (i) as a surface recognition cap group, allowing 
favorable orientation of the hydroxamic acid within the zinc binding pocket of HDAC, and (ii) as 
a delivery vehicle for HDACi through the nuclear-directed transport activity observed in 
interactions between anthracyclines and the proteasome.43  On this basis, we designed two 
classes of conjugates:  a direct DAU-SAHA conjugate and DAU-triazolyl hydroxamate 
conjugates (Figure 3-2).  The latter conjugates were inspired by the previous work that showed 
that the triazole moiety could b incorporated in lieu of an amide bond as a surface recognition-
connecting group in prototypical HDACi.48 
 
3.2 In Vitro HDAC Inhibition 
The HDAC inhibition of DAU-HDACi conjugates 7 and 12 a-d was tested against HeLa 
nuclear extract HDACs using a cell-free assay (Fluor de Lys) as previously described.48  
Overall, these compounds showed inhibition activities against HeLa nuclear extract HDACs, 
with potencies comparable to or exceeding SAHA (Table 3-1).  It is of particular interest that 
compound  7 shows the same level of activity as SAHA.  This suggests that the attachment of 
DAU does not impair the interaction between the HDACi component of the conjugate and the 
HDAC enzyme outer surface residues.  It is also conceivable that the conjugate may adopt a 
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conformation whereby the anthracycline moiety can contribute positively to the interaction with 








































Figure 3-2:  Design of dual-acting Topo II-HDAC inhibitors.  All compounds were 







Table 3-1:  In vitro HDAC inhibition of DAU-HDACi conjugates 
 
Compound n 
















SAHA  65.0 38±2 27±2 1989±156 
DAU  N.D. NT NT NT 
7  64.7 47±3 20±1 220±21 
12a 1 89.9 4600±240 555±36 N.D. 
12b 2 1.6 54±3 30±2 4129±421 
12c 3 0.9 8±0.4 20±0.4 710±43 
12d 4 4.2 11±0.4 19±1 379±37 
a Inhibition was assayed using the Biomol HDAC Fluorimetric Assay/Drug Discovery Kit.  








All triazole-linked conjugates potently inhibit HeLa nuclear extract HDACs with low to 
mid-micromolar IC50’s.  Among these conjugates, 12a is the least active, closely followed by 
12d, which is about 20-fold more potent.  Compounds 12b and 12c have the most potent anti-
HDAC activity, with a slight preference for the six methylene-linked 12c.  Interestingly, the 
triazole-linked compound 12b is 40-fold more potent than the amide-linked 7, despite their 
similar linker length.  Relative to the HDACi standard SAHA, 12c, the most compound in this 
series, is 70-fold more potent (Table 3-1).  These results showed that these conjugates followed a 
similar trend to that observed with aryltriazolyl HDACi.48 
To probe for any HDAC isoform selectivity, possibly conferred by the complex 
anthracycline moiety acting as a surface recognition cap group, the DAU-HDACi conjugates 
were tested against selected recombinant HDACs – HDAC 1, HDAC 6, and HDAC 8.  The 
pattern of HDAC inhibition of these compounds against HDAC 1 and HDAC 6 are similar to 
what we observed with the HeLa nuclear extract with few exceptions.  Specifically, compounds 
7 and 12b have indistinguishable activity against HDAC 1 and HDAC 6 (Table 3-1).  
Additionally, 12a which has a midnanomolar IC50 against HeLa nuclear extract is almost inactive 
against HDAC 1 (IC50 = 4.6 µM) while it maintains decent activity against HDAC 6 (IC50 = 0.6 
µM ).  We are not sure of the cause of this disparity.  In general, these compounds are weaker 
inhibitors of HDAC 8, with the exception of 7, whose anti-HDAC 8 activity is only around 4-
fold less that its anti-HDAC 1 activity (Table 1).  This suggests that 7 is a more indiscriminant 






3.2.1 Molecular Docking of Dual-Targeted HDACi 
To clarify the structural basis for the observed disparity in HDAC inhibition among 
compounds, we performed molecular docking using the AutoDock program .48,49  Compounds 
were docked against a HDAC 1 homology model built from the human HDAC 2 X-ray structure 
(3MAX) coordinates.50  The compounds with the least inhibitory activity (12a) and the best 
activity (12c) were docked in order to clearly delineate the basis of the ~600-fold difference in 
activities.  Additionally, compound 7 was docked because of its distinct structural feature 
compared to 12a-d, namely, the amide-coupled linker. 
Interestingly, compounds 12a and 12c, differing only in linker length, do not bind to the 
same pocket but instead localize to two different pockets on the surface of HDAC 1(Figure 3-
3a).  It is possible that the hydroxyl group on the daunosamine sugar of 12c makes hydrogen 
bonding contacts with the guanidinium group of Arg270 and that the linker chain more 
effectively positions the hydroxamate to the catalytic zinc by entering the active site through the 
top of the channel (Figure 3-3a and Figure 3-4c).  In addition, two of the hydroxyl groups from 
the anthracycline ring of 12c could take part in the H-bonding interaction with the backbone 
carbonyl group of Arg270 and the N-H group of Gly272.  Conversely, compound 12 adopts a 
conformation to accommodate the shorter linker, consequently prohibiting H-bonding with Arg 
270.  Although many hydroxyl groups of 12a’s anthracycline ring make potentially 
compensatory H-bonding contacts with the phenolic group of Tyr201 and the backbone carbonyl 
groups of Gly207 and Pro206 (Figure 3-4a &b), its binding pocket is more solvent-exposed 







Figure 3-3:  Docked structures of Topo II-HDACi conjugates at the HDAC 1 active site.  (a) 
Superposition of low energy conformations of 12a (teal) and 12c (pink).  (b) Overlay of low 






The amide-linked compound 7 binds to a similar pocket, compared to 12c, but it interacts 
with a different set of surface residues that contribute to its binding affinity.  Unlike 12c which 
enters the active site associating with the “top” of the hydrophobic channel, 7 interacts more so 
with the residues on the opposite side of the channel (Figure 3-3b).  Consequently, the 
daunosamine hydroxyl group of 7 cannot interact with Arg270 similar to 12c.  In lieu of this 
interaction, the anthracycline ring of 7 may engage in H-bonding with the backbone carbonyl 
groups of Gly272, Gly268, and Thr304 on the enzyme surface rim (Figure 3-3b and Figure 3-
4e,f).  It is possible that the observed differences in the binding orientations of these compounds 
at the enzyme surface rim could account for the disparity in potencies against HDAC 1. 
 
3.3 In Vitro Topo II Inhibition 
To determine whether the DAU-HDACi conjugates retained their anti-Topo II activity, a 
cell-free DNA decatenation assay was used.  Kinetoplast DNA (KDNA), a catenated network of 
mitochondrial DNA seen in trypanosomes, was used to quantify the conjugates’ Topo II 
inhibition activity according to a literature protocol.54,55  Figure 3-5 shows the results obtained 
from this study.  KDNA and decatenated KDNA marker (lanes 1 and 2, respectively) were used 
as controls.  Treatment of KDNA with Topo II for 10 minutes at 37°C resulted in extensive DNA 
decatenation (lane 3).  As expected, the addition of 50 µM DAU to the decatenation experiment 
resulted in a severe impairment of DNA decatenation (comparing lanes 3 and 4).  Relative to 
DAU, 12a and 12d have lower inhibition, with the worst overall inhibition shown by 12a, the 
conjugate with the four methylene linker (lanes 7 and 8).  Conjugates 12b and 7 inhibited Topo 





   
Figure 3-4:  Docked structures of 12a and 12c within the active site of HDAC1.  (a) Compound 
12a establishes H-bonding interactions between the anthracycline ring and Gly207, Pro206, 
Tyr201.  (b) Orientation of compound 12a near the catalytic zinc in the active site.  (c) 
Compound 12c establishes H-bonding interactions between the anthracycline ring and Arg270 
and Gly272.  (d) Orientation of compound 12c near the catalytic zinc in the active site.  (e) 
Docked structure of 7 reveals H-bonding interaction between the anthracycline ring and 
Gly272,Gly268, and Thr304.  (f) Orientation of compound 7 near the catalytic zinc in the active 







respectively).  Notably, compound 12c had enhanced Topo II inhibition compared to DAU, 
resulting in near total inhibition of decatenation at 50 µM (comparing lanes 4 and 5).  In total, 
these results show that the Topo II inhibition activity of DAU is tolerant of an appropriate 
modification with HDACi groups, and as seen with 12c, such groups could further enhance the 
Topo II inhibition activity of anthracycline derivatives.  The molecular basis of the HDACi 
linker length-dependent enhancement of Topo II inhibition of the dual-acting conjugates is not 
entirely clear.  It is plausible that the placement of the HDACi group of these conjugates within 
the minor groove of DNA, through the daunosamine sugar,56 could further promote drug-DNA 
association, thereby enhancing the stability of the biologically relevant drug-DNA-Topo II 
ternary complex.  Interestingly, 12c also has the most potent inhibition activity against HDAC 1 
(Table 3-1), thereby embodying both optimum anti-HDAC and Topo II inhibition activities 
under these cell free conditions. 
 
 
Figure 3-5:  Decatenation by Topoisomerase II and inhibition with DAU-
HDACi conjugates.  Lanes 1-3:  (1) KDNA, (2) decatenated KDNA marker, 
(3) KDNA and Topo II.  Lanes 4-9:  KDNA, Topo II and 50 µM (4) DAU, (5) 




3.4 Cancer Cell Growth Inhibition by Dual-Acting Topo II-HDACi 
The prospect of biological activity against cancer cells was investigated through cell 
viability measurements of three human cancer cell lines treated with dual-acting Topo II-
HDACi.  IC50 values were quantified using the MTS assay, which measures the reductive 
capacity of functional mitochondria (Table 3-2).  The positive control compounds DAU and 
SAHA inhibit the proliferation of these cell lines with IC50 similar to the values in the 
literature.57,58  DAU shows a cell line-dependent cytotoxicity that varies by as much as 10-fold 
among the three cell lines while SAHA shows no such cell line-dependent effect (Table 3-2).  
Bifunctional compounds 12a-d show linker length-dependent antiproliferative activities that 
closely match the trend of their anti-HDAC activities.  Among the three cell lines investigated, 
these compounds decreased the viability of DU-145 the most, while they are the least cytotoxic 
to MCF-7.  Although less pronounced than the effect seen with DAU, these compounds display 
cell line-dependent cytotoxicity as well.  Nevertheless, the micromolar IC50 values and the 
traction with the anti-HDAC activities suggest that HDAC inhibition is the dominant mode of 
anti-proliferative activities in compounds 12a-d.  Specifically, the antiproliferative activities of 
12c and SAHA, compounds with similar linker length, are virtually indistinguishable against 
DU-145 and SK-MES-1 cell lines.  This is surprising as 12c displays the most potent HDAC and 
Topo II inhibition. 
Interestingly, compound 7, a true hybrid between SAHA and DAU, showed 
the best cytotoxicity of all the bifunctional inhibitors across all cell lines, possessing 
sub-micromolar activities.  In fact, the cytotoxicity of 7 closely rivals that of DAU, 
and they are equipotent against MCF-7.  This is contrary to the trend seen in cell-free 
assays of HDAC and Topo II inhibition.  The potentiation of 7 within the cellular  
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7  0.13±0.06 0.47±0.02 0.99±0.21 
12a 1 5.39±1.02 15.3±3.1 24.5±1.6 
12b 2 1.61±0.29 4.68±0.75 13.4±1.85 
12c 3 2.92±0.31 3.31±0.23 10.6±0.94 
12d 4 2.06±0.33 2.61±0.11 14.8±1.6 
DAU  0.09±0.002 0.17±0.09 0.95±0.05 
SAHA  2.12±0.25 2.42±0.38 2.5±0.61 
a Values are the average of two experiments performed in 

















environment could be due to many factors, including the predominance of the Topo II 
inhibition character in dictating the bioactivity of 7, the indiscriminant inhibition of 
multiple HDAC isoforms, or an alternate mechanism(s) that is unrelated to the 
inhibition of either target. 
 
3.5 Modulation of Cellular Markers Consistent with HDAC Inhibition 
3.5.1 p21 Upregulation and Histone Acetylation 
To gain a better perspective of the molecular mechanisms behind the antiproliferative 
activities observed in response to these dual-acting inhibitors, we probed the effect of their 
exposure on the intracellular status of p21waf1 (p21) in DU-145 cancer cells.  p21 has been shown 
to be upregulated in response to HDACi treatment, as well as in a p53-independent response to 
DOX.59,60  We dosed inhibitors at concentrations near the determined IC50 in DU-145 and 
evaluated protein expression status using western blotting (Figure 3-5).  We controlled for 
equivalent protein loading using anti-actin antibody (Figure 3-5, bottom panel).  As expected, 
SAHA results in marked upregulation of p21, even at 2.5 µM (top panel, lanes 2 and 3).  
However, neither DAU nor 7 shows noticeable upregulation in p21 expression compared to 
control levels (top panel, comparing lanes 4-7 to lane 1).  This trend is reversed with 12b, as a 
dose-dependent upregulation of p21 expression was observed (top panel, lanes 8 and 9).  
Relative to SAHA, however, the extent of p21 upregulation by 12b is lower, though both were 
dosed at the same concentrations.  Since these experiments were done at the IC50 of the 
respective compounds, these results may indicate that 7 and 12b derive their cytotoxic activity 
primarily through Topo II and HDAC inhibition, respectively. Alternatively, the cytotoxic 





Figure 3-6. Immunoblot detection of cellular HDACi markers.  DU-145 cells were 
dosed for 24 hours at the indicated concentrations to probe for acetylated histones H4 
and H3, and p21waf1.  Actin was also probed to show equal loading of protein.  Lane:  
(1) Control; SAHA (2) 2.5 µM, (3) 5 µM; DAU (4) 0.1µM, (5) 0.5 µM; 7 (6) 0.5 µM, 
(7) 1 µM; 12b (8) 2.5 µM, (9) 5 µM. 
 
To further investigate into the prospect of distinct mechanisms of action for 7 and 12b, 
we probed for histone acetylation status in DU-145 cells exposed to the same drug 
concentrations used for p21 immunoblotting.  Intracellular histone acetylation status is a more 
direct indicator of class I HDAC inhibition.  SAHA shows a strong histone H4 acetylation 
(Figure 3-5, 2nd panel, lanes 2 and 3) while DAU and 7 display moderate dose-dependent change 
in acetylation at the concentrations tested (2nd panel, lanes 4 - 7).  Compound 12b shows a strong 
H4 acetylation, with levels close to that of SAHA, at both concentrations (2nd panel, lanes 8 and 
9).  The trend of the drug-induced perturbation of the acetylation state of H3, in core histones 
purified by acid extraction of DU-145 cell nuclear extract, is similar to that obtained for H4.  
Relative to the control, we observed distinct H3 acetylation  in DU-145 cells exposed to the same 
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drug concentrations used for H4 immunoblotting (Figure 3-5, 3rd panel).  These results provide 
evidence supporting the involvement of intracellular HDAC inhibition as part of the mechanisms 
of bioactivity of the dual-acting compounds 7 and 12b.  
3.5.2 Tubulin Acetylation 
Additional data was sought in order to clarify the mechanisms involved in the 
antiproliferative activities and to delineate the disparity in enzyme inhibition versus 
antiproliferative activity.  Tubulin was chosen as a target as it is acetylated by the cytoplamic 
HDAC6,21,61,62 for which 7 and 12b had nearly identical inhibition.  Interestingly, inhibition of 
HDAC6-associated tubulin acetylation has been shown to enhance the cytotoxicity of DNA-
damaging agents.63 While most HDACi induce p21waf1 overexpression, inhibition of tubulin 
deacetylation is compound specific,64 potentially allowing for differentiation between the 
mechanisms and potencies of 7 and 12b.  Because tubulin acetylation in response to HDACi is a 
relatively early event 65, we dosed DU-145 cells for 4 hours with inhibitors at either IC50 
concentrations (Table 2) or a high concentration (~5X IC50).  Immunoblotting revealed highly 
varied levels of tubulin acetylation among the inhibitors.  DAU induced the lowest levels of 
acetylation, with IC50 concentration showing levels comparable with control and only a slight 
increase in response to higher concentration of drug (Figure 3-6, lanes 1-3).  Compound 7 
induced moderate levels of acetylation (Figure 3-6, lanes 4 and 5), while 12b caused robust 
acetylation at 5X its IC50 (Figure 3-6, lanes 6 and 7).  p21 expression at 4 hours remained low 





Figure 3-7:  Tubulin acetylation in response to TopoII-HDACi.  DU-
145 cells were dosed for 4 hours with: (1) Control (0.1% DMSO), (2) 
DAU 90 nM, (3) DAU 500 nM, (4) 7 130 nM, (5) 7 500 nM, (6) 12b 
1.31 µM, (7) 12b 10 µM. 
 
3.6 Intracellular Topo II Inhibition 
To obtain information about the intracellular fate of Topo II upon cell exposure to these 
dual-acting agents, we used an immunoblotting kit to assay compound-induced Topo II 
inhibition in an intracellular environment (Figure 3-7).66  DU-145 cells were dosed with drug 
concentrations corresponding to cell growth inhibition IC50’s while the control cells were dosed 
with vehicle (0.1% DMSO). The relative levels of stabilized Topo II-DNA cleavage complexes 
were determined for a 30 min drug treatment, as recommended by the manufacturer.  Within this 
period, the control cells showed no significant amounts of Topo II inhibition, evidenced by the 
low levels of Topo II associated DNA (Figure 7a, lane 1). Cells treated with DAU and 12b 
contained high levels of Topo II – DNA cleavage complexes, with 12b showing a significantly 
higher amount (Figure 3-7a - lanes 2 vs. 4). This result suggests that 12b could derive its 
cytotoxic activity, in part, from intracellular Topo II inhibition. Conversely, the levels of Topo II 
– DNA cleavage complexes in cells exposed to 7 is indistinguishable from that of the control 
cells (Figure 3-7a, lane 3), suggesting a minimal contribution of Topo II inhibition to the 
cytotoxic activity of 7 within this period. This observation is surprising in light of the seemingly 
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contradictory moderate effect of 7 on H4 acetylation (Figure 3-5), tubulin acetylation (Figure 3-
6) and its potent cell growth inhibition activity (Table 3-2). 
 
Figure 3-8: Intracellular Topo II inhibition.  DU-
145 cells were probed for stabilized DNA-Topo 
II cleavage complexes upon (a) 30 min 
treatment; (b) 72 h treatment with bifunctional 
compounds:  (1) control, (2) 90 nM DAU, (3) 
130 nM 7, (4) 1.6 µM 12b. 
 
To elucidate any contribution Topo II inhibition could be adding to long-term inhibition 
of cell proliferation, Topo II cleavage complexes were assayed after 72 hours of treatment with 
compounds (Figure 3-7b).  As expected, DAU treatment results in significant inhibition of Topo 
II activity relative to control levels (Figure 3-7b, comparing lanes 1 and 2). Compound 7 shows a 
measured increase in Topo II inhibition relative to control levels (Figure 3-7b, comparing lanes 1 
and 3). Interestingly, we observed a drastic drop in the levels of stabilized Topo II-DNA 
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cleavage complexes upon cell exposure to 12b for 72-hour (comparing lane 4 of Figures 3-7a 
and 3-7b). This result suggests that the Topo II inhibition activity of 7 increases with time while 
that of 12b decreases. The persistence of the stabilized Topo II-DNA cleavage complexes over a 
longer period indicates that Topo II inhibition may contribute significantly to the mechanism of 
the antiproliferative activity of 7. 
 
3.7 Intracellular Localization of Dual-Acting Topo II-HDACi 
HDAC1 and Topo II, are nuclear-localized targets of these bifunctional compounds, 
while HDAC6 is cytoplasmic.  To determine whether decreased cell penetration could be one of 
the reasons for the difference in the potencies of compounds 7 and 12b, we used confocal 
microscopy to visualize their intracellular localization (Figure 3-8).  We exposed DU-145 cells to 
1 µM of DAU, 7 and 12b.  After 4 hours incubation time, cells were monitored at 488nm, the 
excitation wavelength (λex) of DAU, and we observed clear differences in the intracellular 
distribution profiles of the tested compounds.  In agreement with previous study in the literature 
67, DAU is localized within the nuclear and perinuclear regions of DU-145 cells.  Although it 
shows a less nuclear localization, compound 7 is more widely distributed within the cytoplasm 
with evidence for perinuclear localization in similar to that of DAU.  In contrast, 12b shows a 
highly diminished intracellular distribution, with the bulk of the compound trapped in vesicle-
like bodies within the cell (Figure 3-8).  The relatively poor intracellular distribution of 12b 
could be due to low cell membrane penetration or an enhanced pump-induced efflux of 
compound from within the cell.68 We obtained a similar result with a lung tumor derived A549 
cells (Figure 3-9). These results show that 7 and 12b have different intracellular residency which 
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may affect access to their targets and consequently offer additional insight into underlying 
factors that could contribute to the disparity in the in vitro potency of these compounds. 
 
 
Figure 3-9:  Intracellular distribution of dual-acting inhibitors in DU-145 cells.  (a) 
DAU, (b) 7, (c) 12b.  Cells were dosed at 1 µM for 4 hours with indicated compounds 




Figure 3-10:  Intracellular distribution of dual-acting inhibitors in A549 lung cancer 
cells.  (a) DAU, (b) 7, (c) 12b.  A549 cells were dosed for 4 hours at 1 µM with the 
indicated compounds and visualized by confocal microscopy.  Confocal microscopy 





There is evidence for the synergistic effect of combined Topo II and HDAC inhibitors on 
cancer.38 However, this synergy is schedule dependent, hence traditional combination therapy 
involving Topo and HDAC inhibitors may be complicated by the inherent pharmacokinetic 
disadvantage of two separate drugs.  To critically delineate the benefits of simultaneous Topo 
and HDAC inhibition in cancer therapy, it will be of interest to identify agents that possess Topo 
and HDAC inhibition activities within a single molecule.  Toward this end, we have created 
dual-acting Topo II/HDAC inhibitors.  A subset of these compounds potently inhibits the 
proliferation of representative cancer cell lines.  When subjected to target-specific screening, 
these agents present both HDAC and Topo II inhibition signatures under cell-free conditions and 
in cell cultures.  This observation suggests that the cytotoxic activities and potency of these dual-
acting compounds could be dictated by either of the two anti-tumor pharmacophores. 
Specifically, results from HDAC and Topo inhibition studies; and p21, acetyl-H4, and acetyl-
tubulin immunoblots highlight compound 7 as a moderate, yet sustained modulator of several 
intracellular targets important in tumor etiology. This may explain the superior antitumor activity 
of compound 7 relative to the other dual-acting agents disclosed in this study. It is, however, 
instructive to emphasize that the target validation experiments described herein are performed 
under different conditions at different incubation periods, so parsing out the specific 
contributions of the two targets to the bioactivity of these agents may not be direct.   
Another target-independent factor which influences the bioactivity of the anthracycline-
derived dual-acting agents is their cellular uptake and/or residency.  In fact, diminished 
intracellular residency, occasioned by multidrug resistance protein (MRP) mediated efflux, is 
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one of the problems of an anthracycline-based chemotherapy regimen.68 Compound 12b shows a 
rapid on-set of HDAC and Topo II inhibition activities which may be quickly lost due to 
diminished intracellular residency. The poor intracellular distribution of 12b may suggest that 
the triazole-containing compounds 12a-d are prone to efflux, in a similar manner to the 
anthracycline template.  Alternatively, it may be that 12a-d are not easily up taken into the cell.  
Either of these limitations would compromise the bioactivity of 12a-d and may explain their less 
than optimal cytotoxic activity, despite evidence for potent inhibition of Topo II and HDACs.    
Nevertheless, the amide-containing compound 7 is a lead that merits additional study due 
primarily to its good intracellular distribution and potency that rivals DAU.  It will be of interest 
to know how 7 fares with respect to common deleterious side effects that have plagued 
anthracycline therapy. 
The compatibility of the HDACi pharmacophore for addition of the large anthracycline 
moiety and the increase in activity against each target when DAU and HDACi were combined to 
form bifunctional Topo II-HDACi caused us to inquire whether combining Topo I and HDAC-
inhibiting functionalities could furnish similar advantages.  Topo I inhibitors are potent 
anticancer agents, causing DNA single strand breaks, cell cycle arrest and apoptosis,69-73 but 
most importantly, HDACi have been shown to act synergistically with Topo I inhibitors, 
resulting in enhanced cancer apoptosis.74  To investigate whether the same dual-targeted strategy 
would prove advantageous, dual-targeted compounds were designed using the camptothecin ring 








Figure 3-11:  Representative structures of camptothecin inhibitors of Topo I (a), and (b) HDACi. 
 
3.9 Design of dual-targeted Topo I-HDACi 
The camptothecin family of Topo I inhibitors are potent anticancer drugs that form a 
ternary complex at the interface of the cleavage complex, inhibiting dissociation of Topo I from 
DNA.  10-hydroxycamptothecin and 7-ethyl-10-hydroxycamptothecin (SN-38) were chosen as 
the Topo I inhibiting templates for the design of dual-targeted Topo I-HDACi due to their 
promising activity against a range of tumor types.  Also, both templates have demonstrated 
considerably more potency and less toxicity that the parent compound, camptothecin.75-77  SAR 
studies on camptothecins have identified substitutions at the C-10 hydroxyl are tolerable78 so 
additions of HDACi linkers through this position were performed using the 1,2,3-triazole ring 
linkage assayed previously (Figure 3-12).48b    In this design, it was anticipated that the 
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camptothecin template might act as an aromatic surface recognition cap group, while retaining its 
Topo I inhibition activity.  We introduced variations in the linker region to test the linker length-
dependent potency of these bifunctional compounds.  Linker lengths were chosen based on the 
optimal HDAC inhibition demonstrated by compounds with five and six methylene linkers in 
previous studies.17,48,79   
 
 
Figure 3-12:  Design of dual-acting Topo I-HDACi. 
Compounds synthesized by Daniel Yao (13a-e), Dr. Vishal Patil (13f-h) 
 
3.10 In vitro HDACi activity 
Building on previous observations regarding the linker length-dependent potency of 
triazole-linked HDACi, 7-ethyl-10-hydroxycamptothecin-derived compounds 13a-e were 
screened for anti-HDAC activity using HeLa nuclear extract as previously described,48 but with a 
slight modification.  Camptothecin has a fluorescence emission close to the wavelength (460 nm) 
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of the fluorescence generated by cleavage of the assay substrate by HDAC.  To circumvent this 
potential interference, control wells containing the same test concentrations were assayed 
similarly, but without HeLa nuclear extract, and the resulting fluorescence readings were 
subtracted from the experimental results.    Compound 13a, the shortest analogue with a three 
methylene linker separating the triazole ring and the hydroxamate moiety, has no measurable 
anti-HDAC activity at concentrations less than 10 µM (Table 3-3).  The inactivity of 13a may be 
due to the fact that its linker is too short to effectively position its hydroxamate moiety within the 
active site while maintaining the crucial surface residue contacts.  Conversely, compounds 13b-e 
displayed linker length-dependent HDAC inhibition activities with compound 13d, an analogue 
with a six methylene linker, having inhibition activities comparable to SAHA (Table 3-3). The 
anti-HDAC activities of these compounds followed linker length-dependence similar to what we 
observed for other aryltriazolyl HDACi.48b 
In order to elucidate the contribution of the ethyl group at the C-7 position toward HDAC 
inhibition, camptothecin-derived compounds 13f-h were synthesized and assayed for anti-HDAC 
activity.  The linker lengths of these compounds were chosen based on the optimal HDAC 
inhibition demonstrated by 7-ethyl-10-hydroxycamptothecin derived compounds 13b-d.  A 
comparison of the anti-HDAC activities of 13b-d and 13f-h, against the HeLa cell nuclear 
extract HDACs, reveals that pairs with the same linker length have nearly identical HDAC 
inhibition activity (Table 3-3).  These results suggest that the presence or absence of the ethyl 
group at the C-7 of the camptothecin ring system has no significant effect on the inhibition of 
HeLa cell nuclear extract HDACs. As expected, SN-38 has no measurable HDAC inhibition 
activity.  For both sets of compounds, the best inhibition activity was observed in compounds 
with a six methylene linker.  Furthermore, these compounds inhibited HeLa nuclear extract 
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HDACs with activities comparable to the standard HDACi, SAHA.  This result suggests that the 
camptothecin ring is a compatible cap group for a dual-targeted HDACi, perhaps facilitating 
HDAC inhibition through interactions with enzyme surface residues, consistent with the 
accepted mode of inhibition. 
 
Compound n R 
HeLa N.E. 
IC50 (nM) 
13a 1 -CH2CH3 N.D. 
13b 2 -CH2CH3 155.4 
13c 3 -CH2CH3 120.7 
13d 4 -CH2CH3 64.65 
13e
 5 -CH2CH3 212.3 
13f 2 -H 144.5 
13g 3 -H 112.2 
13h 4 -H 56.2 
SN-38 - - N.D. 
SAHA - - 65.0 
N.D. – nondeterminable within the tested concentration 





Table 3-4:  HDAC inhibition of dual-targeted Topo I-HDACi against distinct isoforms. 
 
Compound n R HDAC1 IC50 (nM) HDAC 6 IC50 (nM) HDAC 8 IC50 (nM) 
13a 1 -CH2CH3 N.D. 85 ± 34 1726 ± 577 
13b 2 -CH2CH3 NT NT NT 
13c 3 -CH2CH3 129 ± 33 42 ± 6 N.D. 
13d 4 -CH2CH3 50 ± 7 36 ± 5 N.D. 
13e
 5 -CH2CH3 369 ± 111 75 ± 34 2599 ± 475 
13f 2 -H 116 ± 40 260 ± 40 N.D. 
13g 3 -H N.T. N.T. N.T. 
13h 4 -H 37 ± 7 81 ± 26 1046 ± 316 
SN-38 - - N.T. N.T. N.T. 
SAHA - - 38 ± 2 27 ± 2 294 ± 35 
N.D.-nondeterminable within the tested concentration range, 1 nM – 10 µM; N.T. – not tested; 
Data obtained through agreement with BPS Bioscience. 
 
To obtain additional evidence for the specific mode of HDAC inhibition, isoform 
selectivity was investigated by testing selected compounds against pure HDAC1, HDAC6, and 
HDAC8 (Table 3-4).  The pattern of anti-HDAC activities against HDAC1 and HDAC6 mirrored 
what was observed with HeLa nuclear extract results with one exception.  The three methylene-
linked compound 13a is inactive against HDAC1 while it maintains low nanomolar and 
submicromolar IC50’s against HDAC6 and HDAC8, respectively.  In general, these compounds 
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are more selective for HDAC6 with modest to no activity against HDAC8.  The preference and 
stronger activity against HDAC6 over HDAC1 could also provide an alternate explanation for 
the molecular mechanisms behind the inhibition data against HeLa nuclear extract, which is a 
rich source of HDACs 1 and 2.80,81 
  
3.11 In Vitro Topo I Inhibition 
We performed a cell-free DNA plasmid relaxation assay, according to a literature 
protocol, in order to determine the Topo I inhibition activity of these Topo I-HDACi 
conjugates.82,83    In this assay, a supercoiled plasmid is incubated with Topo I in the presence or 
absence of Topo I inhibitors.  Reactions are terminated by addition of SDS, which denatures 
Topo I.  Reaction mixtures are then electrophoresed in an agarose gel and DNA is visualized 
using a nucleic acid dye.  Stabilized cleavage complexes that are covalently bound to DNA will 
inhibit migration of DNA in the gel significantly more, relative to unbound, relaxed DNA.  SN-
38 was used as a positive control for Topo I inhibition and all compounds were tested at 50 µM 
(Figure 3-13).  The 7-ethyl-10-hydroxycamptothecin-derived compounds 13a-e inhibited Topo I 
as demonstrated by the reduction in relaxed plasmid and the increase in nicked plasmid 
compared to uninhibited Topo I (Figure 3-13a, lanes 4-8 vs. 2).  Furthermore, there was little 
apparent drop in activity relative to SN-38 (lane 3).  13f-h inhibited Topo I-induced plasmid 
relaxation with similar activities to each other, but with lesser activities relative to SN-38 (Figure 
3-13b, lanes 4-6 vs. 3).  The difference in inhibitory activities between 13a-e and 13f-h was not 
unexpected and could be explained by the greater potency of SN-38 over camptothecin in 
inhibiting Topo I.84,85  Contrasting with HDAC inhibition, the modification at the C-7 position is 
a significant determinant of Topo I inhibition.  These results, taken together with the HDAC 
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inhibition data, showed that these dual-targeted Topo I-HDACi can function to inhibit either 
target enzyme and conjugation of the two inhibiting moieties does not preclude the activities of 



























Figure 3-13:  Topoisomerase I-induced plasmid relaxation assay. 
(a)  (Lane 1) PBR322 plasmid DNA; (Lane 2) DNA and Topo I; Lanes 3-8: DNA, Topo I 
and 50 µM:  (3) SN-38; (4) 13a; (5) 13b; (6) 13c; (7) 13d; (8) 13e. 
(b)  (Lane 1) PBR322 plasmid DNA; (Lane 2) DNA and Topo I; (Lanes 3-6)  DNA, Topo 




3.12 Anticancer activity of Topo I-HDACi 
To examine the preliminary effects of these dual-acting inhibitors on cancer cell 
proliferation, they were screened against the DU-145 prostate cancer cell line and the inhibition 
of cell viability was measured.  SN-38 and SAHA were used as positive controls with SN-38 
potently inhibiting DU-145 viability in the mid-nanomolar range, while SAHA’s IC50 was 
higher, in the low micromolar range.  Compound 13a-e displayed linker length-dependent 
anticancer activities with a five methylene linker proving optimal for inhibiting viability (Table 
3-5).  Compound 13a, with the shortest linker of three methylenes, possessed the least potent 
activity against DU-145. 
Conversely, compounds 13f-h displayed indistinguishable anticancer activities with 
IC50’s around 2 µM.  Comparatively, most of the 7-ethyl-10-hydroxycamptothecin-based 
compounds are less active than their10-hydroxycamptothecin-based congeners.  One exception is 
compound 13c which showed anticancer activity that it identical to that of 13g, its direct analog.  
More importantly, the micromolar activities suggest that HDAC inhibition may be the 










Table 3-5: Anticancer activity of Topo I-HDACi 
 
Compound n R IC50 (µM) 
13a 1 -CH2CH3 6.27 
13b 2 -CH2CH3 4.25 
13c 3 -CH2CH3 2.05 
13d 4 -CH2CH3 3.11 
13e 5 -CH2CH3 3.51 
13f 2 -H 2.50 
13g 3 -H 1.95 
13h 4 -H 2.03 
SN-38 - - 0.11 
SAHA - - 2.12 
All values are the mean of two experiments 
performed in triplicate as measured by the MTS 
assay (Promega).  DU-145 was dosed for 72 hours 
with drug. 
 
3.13 Immunoblotting of p21
waf1
 levels in response to Topo I-HDACi. 
Since the anticancer activities displayed by Topo I-HDACi against DU-145 appeared to 
be driven by HDACi-based mechanisms, we profiled the contribution of intracellular HDAC 
inhibition through the level of p21waf1 expression.  Compounds 13c and 13g were used, premised 
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on the fact that they are representative examples from the two Topo I inhibiting templates with 
identical anticancer activities.  Inhibitors were dosed at concentrations near the determined 
1C50’s in DU-145 and p21
waf1 expression was probed via immunoblot (Figure 3-14).  Equivalent 
protein loading was demonstrated using an anti-actin antibody (Figure 3-14, top panel).  Both 
SAHA and SN-3886 resulted in marked upregulation of p21waf1 expression levels with 24 hour 
treatment (Figure 3-14, bottom panel, lanes 2-5).  Gratifyingly, we observed that the dual-acting 
Topo I-HDACi 13c caused a dose-dependent increase in p21waf1 expression (Figure 3-14, bottom 
panel, lanes 6 and 7).  Moreover, 13g resulted in substantial upregulation of p21waf1 expression 
with levels comparable to SN-38 (Figure 3-14, bottom panel, lanes 8 and 9).  These results 
provide an initial molecular basis for the observed anticancer activity of Topo I-HDACi.  It is 
unknown at present how much of the p21waf1-dependent anticancer activity is contributed by 
each inhibiting moiety as both SAHA and SN-38 significantly increased p21waf1 expression.  
Subsequent investigation into the expression levels of other cellular markers could clarify the 
driving force behind the cellular effects observed. 
 
 
Figure 3-14:  Immunoblot of p21waf1 expression changes in response to 
Topo I-HDACi.   
Lanes: (1) Control, (2) SAHA, 2.5 µM, (3) SAHA 5.0 µM, (4) SN-38, 0.1 
µM, (5) SN-38 0.5 µM, (6) 13c, 2.5 µM, (7) 13c, 5.0 µM, (8) 13g, 2.5 µM, 






A new class of dual-targeted Topo I-HDACi has been created from camptothecin and 
SAHA-like templates.  Two types of camptothecin templates were used and both were connected 
through their 10-hydroxy moieties to alklyltriazolyl hydroxamates that we have shown possess 
enhanced HDAC inhibition activity.48b  Results from in vitro and whole cell studies showed that 
these compounds possess inhibition activities against both target enzymes and inhibit the growth 
of DU-145 prostate carcinoma cells.  Relative to the camptothecin standard SN-38, the 
functionalization of the 10-hydroxy moiety presented no observable deleterious effect on the 
Topo I inhibition by 7-ethyl-10-hydroxycamptothecin-derived conjugates 13a-e and only minor 
attenuation in the inhibitory activities of 10-hydroxycamptothecin-derived conjugates 13f-h at 
the concentration tested (50 µM).  Despite their potent Topo I inhibition activities in cell-free 
DNA plasmid relaxation assays, these compounds displayed anticancer activities against DU-145 
cells at levels more comparable to the HDACi standard SAHA.  One plausible explanation for 
this observation is that the functionalization of the 10-hydroxy moiety may negatively impact the 
binding of these conjugates to Topo I as crystallographic evidence suggests that the 10-hydroxy 
group is involved in a hydrogen bonding interaction with a water molecule oxygen at the Topo I 
active site.87  Alternatively, the ability of these conjugates to interact with other tumor growth-
inhibiting secondary targets of camptothecins88,89 may be compromised. 
Overall, these compounds show promise as potent anticancer agents with the potential to 
broadly arrest tumor growth by inhibiting two essential enzymes.  Further work is needed to 
better elucidate the specific mechanisms responsible for the activities of these compounds.  
Several avenues for investigation could achieve this aim.  First, the intracellular Topo I inhibition 
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could be profiled by immunoblotting of stabilized cleavable complexes to determine the relative 
contribution of Topo I inhibition to the overall anticancer activity.  Also, since camptothecins are 
fluorescent, their subcellular localization 90could be easily determined.  The specific subcellular 
distribution of these compounds could be used to form indirect conclusions about the 
mechanisms underlying their anticancer activities and also serve as a basis for their differences in 
activity relative to each other.  Furthermore, the HDACi mechanisms involved could be further 
probed via histone acetylation blots and, since these compounds were isoform selective towards 
HDAC6, tubulin acetylation could be investigated.  Finally, second generation conjugates that 
retain the 10-hydroxy moiety on the camptothecin template could be used to profile whether 
addition of the HDACi moiety through the C-10 hydroxy group decreases efficacy by negatively 
affecting Topo I binding.  If this is the case, an alternate design may prove better suited to Topo I 
inhibition, and possibly HDAC inhibition as well. 
 
3.15 Experimental 
3.15.1 In Vitro HDAC Inhibition 
In vitro HDAC inhibition was assayed using the HDAC Fluorimetric Assay/Drug 
Discovery Kit as previously described.48  Briefly, 15 µL of HeLa nuclear extract was mixed with 
5 µL of 10× compound and 5 µL of assay buffer.  In order to control for anthracycline 
fluorescence, an extra set of control wells were used in which compounds were diluted to HDAC 
test concentrations and assayed as normal, but without HeLa nuclear extract.  Fluorescence 
values generated in these wells were subtracted from test well means to eliminate fluorescent 
contribution from the anthracycline.  This method was also used for camptothecin-derived 
compounds.  Fluorogenic HDAC substrate (25 µL) was then added, and reaction was allowed to 
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proceed for 15 min at room temperature and then stopped by addition of a developer containing 
TSA.  Fluorescence was monitored after 15 min at excitation and emission wavelengths of 360 
and 460 nm, respectively. IC50 values were determined using logit plots. 
3.15.2  In Vitro Topo II Decatenation Assay (Josh Canzoneri) 
The decatenation of KDNA was assayed according to TopoGen protocol in order to 
determine topoisomerase II activity.  The substrate KDNA (200ng) and 50µM drug were 
combined in assay buffer (50 mM Tris–HCl, pH 8, 120 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 
0.5 mM dithiothreitol, 300ug/ml bovine serum albumin (BSA)) and incubated for 10 min on ice.  
Next, 1 U of topoisomerase II was added and the reaction was allowed to proceed for 10 min at 
37°C.  The reaction was quenched via the addition of loading buffer (1% sarkosyl, 0.025% 
bromophenol blue, and 5% glycerol), and was then analyzed by electrophoresis on a 1% agarose 
gel in TBE buffer (89 mM Tris, 89 mM borate, and 2 mM Na–EDTA, pH 8.3) for 3.5 h at 40 V.  
The gel was stained with SYBR Green I (Molecular Probes) for 30 min and was visualized under 
UV illumination and photographed on an AlphaImager. 
3.15.3  Cell Culture and Viability 
DU-145 prostate carcinoma and SK-MES-1 non-small cell lung carcinoma was obtained 
from ATCC (Manassass, VA) and maintained in the recommended growth mediums.  MCF-7 
breast cancer cells were a generous gift from Dr. Donald Doyle.  All cell lines were maintained 
in a 37°C incubator with a 5% CO2 environment.  All compounds to be tested were dissolved to a 
concentration of 10 mM in DMSO and stored at -80°C.  Cells were passaged 24 h prior to cell 
viability experiments.  For cancer cell viability experiments, cells were dosed for 72 h and 
viability was determined both by Trypan Blue staining and/or through the use of the MTS assay 
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(Promega) according to manufacturer’s instructions.  Control wells were dosed with fresh media 
containing 0.1% DMSO. 
3.15.4  Intracellular Topo II Inhibition 
DU-145 cells were probed for Topo II inhibition with an in vitro blotting kit designed to 
show relative amounts of stabilized Topo II-DNA cleavage complexes (Topoisomerase II In Vivo 
Link Kit, Topogen).  Briefly, cells were dosed with Topo II-HDACi’s at concentrations 
pertaining to their respective IC50 values for cell viability inhibition.  Control cells were dosed 
with 0.1% DMSO to take into account DMSO from stock solutions of drug.  As recommended in 
the protocol instructions, cells were dosed for 30 minutes, counted, and lysed with 1% sarkosyl.  
Alternately, DU-145 cells were dosed for 72 hours, counted, and equalized with the cell count 
from the 30 min incubation before subsequent lysis.  Lysate was collected, loaded on a CsCl 
gradient, and subjected to centrifugation at 31,000 RPM at room temperature for 12 hours.  
Aliquots of the gradient separations were then taken and the Topo II-DNA cleavage complexes 
were identified via absorbance at 260 nm.  Aliquots were then loaded into a slot blotting device 
and subjected to vacuum to load proteins onto a nitrocellulose membrane.  Immunoblotting using 
the Odyssey Imaging System (LiCor Biosciences) revealed Topo II levels associated with the 
stabilized DNA complexes. 
3.15.5  Immunoblotting of p21
waf1
 and Histone Acetylation 
DU-145 prostate cancer cells were passaged 24 h prior to the experiment.  Compounds to 
be tested were diluted in the growth medium so that the final concentration of DMSO was 0.1% 
and control cells were dosed with fresh media containing 0.1% DMSO.  Cells were dosed for 24 
h, then washed twice with ice-cold PBS, and lysed on the culture plate at 4°C for 5 min with 
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RIPA buffer containing protease inhibitors.  Lysates were mixed repeatedly by pipetting and 
centrifuged at 14,000 X g for 15 minutes at 4°C.  Supernatant was saved and protein 
concentration was quantified using the Bio-Rad Protein Assay (Bio-Rad) with BSA as the 
standard.  For histone samples, the nuclear pellet was saved after centrifugation and washed with 
RIPA buffer.  Pellets were resuspended in 0.2 N HCl and acid extracted overnight at 4°C.  
Samples were centrifuged at 6500 x g for 10 minutes at 4°C and the supernatant was saved and 
protein content was quantified using the Bio-Rad Protein Assay. 
Loading buffer was added and protein samples were incubated at 100°C for 10 min 
before electrophoresis.  Proteins were then transferred to a nitrocellulose membrane for 1 h, 
followed by blocking overnight in a 1:1 mixture of Odyssey Blocking Buffer (LiCor 
Biosciences) and PBS.  Membranes were incubated with primary and secondary antibodies, both 
diluted in 1:1 Odyssey Blocking Buffer/PBS.  Membranes were scanned on the Odyssey infrared 
imaging system (LiCor Biosciences) using both 700 nm and 800 nm channels simultaneously at 
169 µm resolution and analyzed on the imaging software. 
3.15.6  Immunoblotting of Tubulin Acetylation 
DU-145 cells were passaged 24 hours prior to dosing.  Compounds were diluted such that 
cells, including controls, were exposed to no more than 0.1% DMSO.  Cells were dosed for 4 
hours before lysis in RIPA buffer with protease inhibitors.  Lysates were vortexed and 
centrifuged at 14,000 RPM at 4°C for 15 minutes.  Supernatants were removed and protein 
concentration was assayed using the Bio Rad Protein Assay with BSA as a standard.  
Electrophoresis and immunoblotting were performed as described above.  Rabbit anti-tubulin 
(Sigma) and mouse anti-acetyl tubulin (Invitrogen) were used to probe the membrane after 
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blocking with Odyssey Blocking buffer (Li Cor).  Li Cor near-infrared secondary antibodies 
were used to image the blot with the Odyssey infrared imaging system at 700 and 800 nm. 
3.15.7  Intracellular Localization of Topo II-HDACi  (Josh Canzoneri) 
Cells were plated on glass coverslips in 35mm dishes 24 h before the experiment.  They 
were then incubated with fresh media containing the indicated compounds at concentration of 1 
µM.  After 4 hours, cells were washed with PBS   Cover slips were then mounted and viewed 
under a confocal microscope (DAU λex = 488nm,; Zeiss LSM 510 UV confocal microscope). 
3.14.8 Topo I-induced DNA Plasmid Relaxation Assay (Josh Canzoneri) 
The drug-induced formation of cleavable complexes was conducted in 10 mM Tris-HCl, 
pH 7.9, 1 mM EDTA, 0.15 M NaCl, 0.1% BSA, 0.1 mM spermidine, 5% glycerol. A 250-ng 
aliquot of pBR322 plasmid DNA (NEB) was mixed with the drug of interest and allowed to 
equilibrate at room temperature for 20 minutes. Next, reactions were placed on ice and 4 U of 
human topoisomerase I (Topogen) was added to a 20-ml total mixture volume. Each sample was 
incubated at 37°C for 30 minutes, then the formation of complexes was terminated by the 
addition of 2 ml of 10% SDS and 2 ml of 0.5 mg/ml Proteinase K (Ambion). The mixtures were 
subsequently incubated for 30 minutes at 37°C, then mixed with 2 ml of loading solution (25% 
bromophenol blue, 50% glycerol) and extracted with 20 ml of 24:1 chloroform/isoamyl alcohol. 
Samples were then analyzed by electrophoresis for 16 hours at 30 V on a pre-run (1 h at 30V) 
1% agarose gel in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0, containing 0.5 mg/ml 
ethidium bromide). After electrophoresis, the gel was stained with a 1:10,000 dilution of SYBR 
Green (Molecular Probes) in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) at 4°C for 30 
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minutes on a rocker, and was then digitally photographed under transillumination with 300-nm 
UV light. 
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Lung-Targeted Macrocyclic HDAC Inhibition 
 
The promise of HDACi as a viable therapeutic strategy, evinced initially through the in 
vitro inhibition of multiple cancer cell types through multiple antiproliferative mechanisms and 
later with the FDA approvals of SAHA and FK-228, has recently been somewhat overshadowed 
with lingering questions about their applicability for the treatment of solid tumors.1  Moreover, 
cardiac side effects, namely QTc prolongation observed with virtually every HDACi, and the 
cardiotoxicity observed in one clinical trial with FK-228 have been cause for concern.1,2  
Additionally, the discovery that different tumor types dysregulate specific HDAC isoforms3 has 
made the design and validation of isoform-selective HDACi an attractive goal that has 
unfortunately been hampered by the lack of crystal structures for most HDAC enzymes.4  
Additionally, this approach has also been complicated by the discovery that certain HDAC 
enzymes are functionally redundant with others.  A complimentary strategy to address these 
issues could be to design tissue-specific HDACi, which could target solid tumors of a particular 
tissue while limiting side effects caused by off-target residency. 
Lung cancer is both the second most common cancer by incidence and accounts for the 
highest mortality in both sexes, making it an essential target for chemotherapeutic development.5  
Additionally, lung cancer is known to upregulate class I HDACs, specifically HDACs 1 and 33, 
and combined treatment with SAHA, carboplatin, and paclitaxel has shown promising in vivo 
responses over carboplatin, paclitaxel and placebo.6  It is possible that a lung-targeted HDACi 
could inhibit the dysregulated HDAC isoforms, allowing for more precise definition of the 
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HDAC-specific contributions to the malignant phenotype, as well as selectively accumulating in 
concentrations conducive to effective treatment of solid lung tumors.  We believed an 
appropriate framework to design lung-targeted HDACi could incorporate complex cap groups 
that could selectively interact with distinct HDAC isoforms while serving as a lung-targeting 
moiety. 
 
4.1 Design of Lung-Targeted Macrocyclic HDACi 
All HDACi currently reported, including the aryl hydroxamates, benzamides, short-chain 
fatty acids, electrophilic ketones, and macrocyclic peptides, fit the classical three-motif 
pharmacophoric model (Figure 2-1).7  Of these, the macrocyclic peptide class of inhibitors 
possess the most complex cap groups, affording the greatest opportunity for modulating the 
biological activities of HDAC enzymes through isoform-selective inhibition.  Although the 
cyclic-peptide HDACi possess potent nanomolar HDAC inhibition activities, their broader 
application in cancer therapy remains unproven.7  One exception, FK-228, is currently FDA-
approved for the treatment of cutaneous T-cell lymphoma and displays an selective inhibition 
profile for class I HDACs.8,9 
The dearth of clinically-effective cyclic-peptide HDACi could arise in part due to 
developmental problems common to large peptides, such as poor oral bioavailability.  In addition 
to the pharmacologically disadvantaged peptidyl backbone, cyclic-peptide HDACi offer limited 
opportunity for side chain modifications and are stereochemically constrained, in the case of the 
cyclic tetrapeptide HDACi.10  Identification of nonpeptide macrocyclic HDACi could afford a 
novel class of compounds with more biologically favorable characteristics, as well as further 
enhance the understanding of the roles of specific interactions with residues on the outer surfaces 
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of HDAC enzymes.  Most importantly, an appropriate peptidomimetic would need to retain 
efficacy as a cap group within the HDACi pharmacophore while selectively directing the small 
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Figure 4-1:  Selected examples of linear HDACi (a), representative cyclic-peptide HDACi (b), 





Macrolides are glycosylated polyketide antibiotics that have been in clinical use for more 
than 50 years for the treatment of respiratory tract infections (Figure 2-1).  Macrolides also 
possess other pharmacologically favorable, non-antibiotic properties, such as anti-inflammatory 
and immunomodulatory effects, that make them promising candidates for the management of 
chronic diseases affecting airway inflammation.11,12  Most importantly, macrolides possess 
favorable pharmacokinetic properties that distribute the drug to the lungs preferentially, possibly 
through a macrophage-dependent mechanism, in high and sustained concentrations.13-16  
Additionally, macrolides derived from the 6-O-methylerythromycin A ring have been reported to 
serve as nonpeptide surrogates for the peptide backbone of macrocyclic peptide luteinizing 
hormone-releasing hormone (LHRH) receptor agonists.17  The advantageous pharmacology and 
peptidomimetic nature of macrolides fit optimally within a lung-targeted design and we 
hypothesized that an appropriate substitution of the cyclic peptide moiety of a prototypical 
cyclic-peptide HDACi with macrolide skeletons could generate a novel class of potent, 
nonpeptide, lung-targeted macrocyclic HDACi. 
In order to test this hypothesis, a SAHA-macrolide conjugate was sought that would 
incorporate the 12-membered azalide ring of azithromycin as the macrolide template (Figure 2-
1).  The azithromycin skeleton is attractive due to its excellent pharmacokinetic profile and the 
ease of chemical transformation of key moieties on the skeleton.18  The design approach 
necessitated attachment of the HDACi linker and ZBG to the macrolide remote from the 
macrocyclic ring, as we anticipated that a potential steric hindrance might occur at the HDAC 
active site due to the introduction of the azithromycin skeleton, a macrocyclic ring not optimized 
for HDAC binding.  After studying the NMR19 and 3D structure, the 3’ amine was chosen as the 
position best suited for modification with a HDACi moiety as there are well established 
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transformations of the tertiary amine moiety,17,18 and almost all modifications at this position 
attenuate antibacterial activity.18b  Two compounds were synthesized with SAHA-like moieties 
attached at the 3’ tertiary amine, macrocyclic depsipeptide 8 and the descladinose depsipeptide 
10 (Figure 4-2).   
 
 
Figure 4-2:  Structures of macrocyclic depsipeptides 8 and 10, with methyl ester precursor, 7.  
Synthesized by Dr. Yomi Oyelere. 
 
4.2 In Vitro HDAC Inhibition by Macrocyclic HDACi 
4.2.1 Inhibition of HeLa Nuclear Extract HDACs 
The inhibition of HDAC by macrocyclic depsipeptides was assayed using a cell-free kit 
assay (Fluor de Lys, Biomol) which revealed concentration-dependent inhibition of HeLa 
nuclear extract, containing high concentrations of HDACs 1 and 2.  Both 8 and 10 have identical 
anti-HDAC activity, with IC50 values in the low nanomolar range(Table 4-1).  Conversely, 
compound 7, the methyl ester precursor of 8, is devoid of activity in this assay.  This result 
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suggests that the azithromycin macrolide is an appropriate cap group substitute for that of typical 
cyclic-peptide HDACi.  Additionally, it is possible that these compounds bind in an orientation 
that facilitates effective hydroxamate placement to chelate the Zn2+ ion while orienting the 
cladinose sugar away from enzyme residues, thus explaining the identical activities of 8 and 10. 
 
Table 4-1:  In vitro HDAC inhibition of 
nonpeptide macrocyclic HDACi 
Compound 










a IC50 values were determined using the 
Biomol HDAC Fluorimetric Assay/Drug 
Discovery Kit. N.D. : not determinable. 
 
We then initiated a structure-activity relationship (SAR) study on 8 and 10 in order to 
optimize the HDAC binding affinity of these compounds.  The linker-cap group connecting 
moiety, macrolide skeleton, and linker length are three fragments that were altered in an attempt 
to arrive at optimal anti-HDAC activity.  The AutoDock program20 and the crystal structure of 
histone deacetylase-like protein (HDLP)21 were both used the guide the structural optimization.  
In an earlier study, we demonstrated the utility of the 1,2,3-triazole ring as an alternative linker-
cap group connection moiety in SAHA-like HDACi.22 Accordingly, we tested the compatibility 
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of the triazole ring with the anti-HDAC activity of 8 and 10, using the triazole-connected analogs 
16a and 16b, respectively (Figure 4-2). 
 
  
Figure 4-3:  Azithromycin-based nonpeptide macrocyclic HDACi.  
Synthesized by Drs. Yomi Oyelere and Bob Chen 
 
Surprisingly, HDAC inhibition studies revealed that the triazolyl compounds 16a and 16b 
have virtually identical anti-HDAC activity as the amide compounds 8 and 10 (Table 4-1).  This 
result contrasts with our previous observation that incorporation of the triazole ring led to an 
enhancement in anti-HDAC activity in SAHA-like HDACi.22  To gain a greater understanding of 
the molecular interactions dictating the activities of these nonpeptide macrocyclic HDACi at the 
HDAC active site, 16b was docked on HDLP using AutoDock as previously described.20,22  
HDLP was chosen because it shares conserved active site residues with class I HDACs.21  
Additionally, direct docking experiments using this structure or a HDAC1 homology model built 
from the same HDLP structure have given docking results with essentially the same quality and 
agreement with experimental data.  Either of these approaches has been extensively used in the 
literature to interrogate the binding interactions of HDAC inhibitors at the enzyme active site.20b,c   
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Docked structures indicated interesting molecular surface complementarity between 16b 
and the HDAC outer rim.  Previous investigations have shown that there are four possible 
binding pockets on the HDLP surface whose interactions with the HDACi cap groups could 
enhance inhibitor binding activity.20b  Compound 16b adopts a docked structure that placed the 
macrolide macrocyclic ring in binding pockets 1 and 3 (Figure 4-3a).  In addition, the 
hydrophobic parts of the macrolide ring optimally interact with the hydrophobic residues in 
pocket 1 and 3 while the hydrophilic groups orient away from the pocket’s hydrophobic residues.  
Compared to the structure of SAHA, 16b binds such that the hydroxamate is removed farther 
from the Zn2+ ion (Figure 4-3b).  From this result, it was inferred that optimizing the length of 
the linker region could place the hydroxamate deeper in the channel to chelate the Zn2+ ion, 
thereby enhancing HDAC inhibition.   
 
                
 
Figure 4-4:  Docked structures of 16b (blue) and SAHA (yellow) on the HDLP active 




Based on the encouraging compatibility of the azithromycin macrolide ring as a HDACi 
cap group, further SAR studies focused on optimizing the linker chain and macrolide cap group.  
The 15-membered azithromycin macrolide was replaced with a 14-membered clarithromycin 
macrolide in 24a-d, and the linker chain was lengthened for both sets of compounds (Figure 4-
5).  Further docking analyses of analogs of 16b with longer methylene linker lengths revealed 
that 16d, a six-methylene analog of 16b, optimally interacts with the Zn2+ ion (Figure 4-6a).  
Interestingly, compound 24d, an analog of 16d in which the 15-membered azithromycin ring has 
been replaced with the 14-membered clarithromycin ring, shows a slight preference for the 
enzyme.  Closer analysis of docked structures of 16d and 24d showed that the C12-C14 region 
of the larger 15-membered ring is about 0.5 Å closer to the phenyl ring of Phe338, a residue that 


















16a, n = 1, R = cladinose
16b, n = 1, R = H
16c, n = 2, R = cladinose
16d, n = 2, R = H
16e, n = 3, R = cladinose
16f, n = 3, R = H
16g, n = 4, R = cladinose





Figure 4-5:  Nonpeptide macrocyclic HDACi based on azithromycin (16 series) 




     
 
Figure 4-6:  Docked structures of 16b (blue) and 16d (orange).  Hydroxamate positioning (a).  
Macrolide ring interactions of 16d (orange) and 24d (yellow) with the HDLP surface (b).  
Docking by Dr. Bob Chen. 
 
In order to experimentally test whether there is a preference for the 14-membered 
macrolide cap group, indicated through in silico results, compounds 16c-h and 24a-h were tested 
against HeLa nuclear extract to assay for anti-HDAC activity.  HDAC inhibition results revealed 
activities that essentially parallel the in silico prediction (Table 4-2).  The compounds displayed 
both linker-length and macrolide-type dependent HDAC inhibition activities.  For both types of 




HDAC activity.  Further increases in linker length past six methylenes did not improve HDAC 
inhibition and were detrimental to function in longer linker lengths.  For compounds with five- 
and six-methylene linkers, head-to-head comparisons revealed that the 14-membered compounds 
are around 2- to 5-fold better HDACi than their 15-membered counterparts (Table 4-2, compare 
16d and 24d, for example).  However, this preference dissipated with increasing linker lengths.  
This is presumably due to the relief of the steric clash between the macrocyclic ring and the 
phenyl ring of Phe338, along with less optimal cap group placement, conferred by the longer 
linkers. 
4.2.2 HDAC8 Inhibition and Intra-Class I HDAC Selectivity 
We then probed for evidence of HDAC isoform selectivity of the macrocyclic HDACi by 
testing for HDAC8 inhibition activity.  HDAC8 was chosen because it is in the same class as 
HDACs 1 and 2, the principal HDACs contained in HeLa nuclear extract used to preliminarily 
determine anti-HDAC activity.  Moreover, there are very few examples of HDAC inhibitors that 
are selective for HDAC isoforms within the same class; therefore use of HDAC8 allowed for a 
quick, yet rigorous assessment of HDAC isoform selectivity inherent to these compounds.  
Compared to SAHA, all nonpeptide macrocyclic HDACi tested were more selective for HDAC 
1/2.  In particular, six methylene-linked 14-membered compounds 24c and 24d are several-fold 
more selective than their 15-membered counterparts (Table 4-2).  Although HDLP and HDAC8 
share similar amino acid sequences and topology at the active site, X-ray crystallography data of 
HDACi bound to HDAC8 has revealed significant inhibitor-specific changes in the enzyme 
active site topology of HDAC8.23  Our docking analysis operates in a rigid receptor mode, and is 
therefore incapable of capturing such crystallographically-observed ligand-induced changes.   
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Table 4-2:  In vitro HDAC inhibition (IC50) and isoform selectivity of 





















a IC50 values were determined using the Biomol HDAC Fluorimetric Assay/Drug 
Discovery Kit.  b Values determined using the Fluor de Lys HDAC8 Fluorimetric Drug 
Discovery Kit.  c Calculated by dividing the anti-HDAC8 IC50 by the anti-nuclear extract 
IC50.  N.D. : not determinable.  NT: not tested. 
Compound 












7 N.D. NT N.D. 
8 107.1 6680 62 
10 109.8 2320 21 
16a 91.6 4730 51 
16b 88.8 3740 42 
16c 13.9 994 72 
16d 10.6 1020 97 
16e 58.9 7130 121 
16f 72.4 6780 94 
16g 145.5 11050 38 
16h 226.7 N.D. N.D. 
24a 37.0 3990 108 
24b 44.3 4750 107 
24c 4.1 1890 462 
24d 1.9 1390 743 
24e 55.6 5880 106 
24f 123.0 4420 36 
24g 169.8 10550 56 
24h 223.4 N.D. N.D. 
SAHA 65.0 1860 29 
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Nevertheless, we docked 16b on the HDAC8 structure reported by Somoza et al.23  
Contrasting with the docked structure on HDLP, the orientation of 16b on HDAC8 is such that 
the linker and ZBG adopt a closed conformation at the entrance to the active site.  In this 
conformation, the linker coiled around the macrocyclic ring and oriented the hydroxamate 
toward the Z n2+ ion, albeit much farther away than possible for any stabilizing interaction to 
occur (Figure 4-7).  An alternate, lower energy conformation of 16b oriented the hydroxamate 
away from the Zn2+ ion.  Therefore, it is possible that the observed isoform selectivity may be 
due to the nonpeptide macrocyclic HDACi’s inability to effectively induce active site 
conformational changes requisite for HDAC8-specific inhibitor binding to the active site.24  
HDAC8 activity has also been observed to depend on the sequence of its peptide substrate,25 so it 
is also possible that enzyme inhibition, and consequently isoform selectivity, may depend on the 
specific substrate tested. 
 
  
Figure 4-7:  Docked structure of 16b with HDAC8 surface (a) and active site (b).  Docking 
experiment performed by Dr. Bob Chen. 
 




4.2.3 HDAC6 Inhibition and Class I/II Isoform Selectivity 
HDAC isoform selectivity of selected macrocyclic HDACi was further tested against 
HDAC6, a representative member of class II HDACs.  Compounds 16c and 16d, and 24c and 
24d, were chosen because they were the most potent 15- and 14-membered macrocyclic HDACi, 
representatively (Table 4-2).  A cell-free HDAC6 inhibition assay was performed as 
recommended by the supplier (Biomol).26  Contrary to SAHA, which inhibited HDACs 1/2 and 
HDAC6 equally, macrocyclic HDACi continued to display a preference for class I HDACs 
(Table 4-3).  This observation is in agreement with the literature, suggesting that complex cap 
groups tend to promote isoform selectivity.7,27 
 













16c 13.9 78.0 6 
16d 10.6 117.4 11 
24c 4.1 89.3 22 
24d 1.9 148.5 78 
SAHA 65.0 85.5 1 
a HeLa Nuclear Extract comprised mainly of HDACs 1  
and 2.  b calculated by dividing the IC50 of HDAC6 by 
the IC50 of HDAC1/2.  All data was obtained from the 





4.3 Cancer Cell Growth Inhibition 
4.3.1 Inhibition of Cancer Cell Viability by Macrocyclic HDACi 
The anticancer activity of macrocyclic HDACi was tested against three transformed cell 
lines:  SK-MES-1 (human NSCLC), NCI-H69 (human SCLC), DU-145 (human prostate cancer).  
Table 4-4 shows the calculated IC50 values for each compound tested through trypan blue 
exclusion, as previously described.28,22  The IC50 values obtained for SAHA closely agree with 
reported values under similar experimental conditions.29  Macrocyclic methyl ester 7, the 
precursor to compound 8 (Figure 4-2), has no effect on cell viability (data not shown), which 
may not be surprising since compound 7 has no HDAC inhibition activity (Table 4-1).  
Unexpectedly, macrocyclic depsipeptides 8 and 10 did not inhibit DU-145 in the tested 
concentration range (0.5 - 25 µM).  Conversely, all triazole-linked macrocyclic HDACi inhibited 
all transformed cell lines tested.  Specifically, compounds 16b, 24c, and 24d are at least twice as 
potent as SAHA in DU-145 (Table 4-4), a cell line known to respond to HDACi.30  
Gratifyingly, macrocyclic HDACi potently inhibit both lung cancer cell lines with a 
preference for 5 and 6 methylene linkers in 15- and 14-membered macrolide compounds.  We 
selected these compounds as leads for further study in an in vivo model relevant for lung cancer 
chemotherapeutic validation.   Most importantly, none of the tested macrocyclic hydroxamates 
show any growth inhibitory effects on either normal human primary lung fibroblasts or human 
mammary epithelial cell lines at concentrations up to 10 µM (Table 4-4).  These data show that 
the macrocyclic compounds are selectively toxic to the transformed cells, a property often 

















8 NT NT >25 NT NT 
10 NT NT >25 NT NT 
16a 1.79 1.92 1.45 >10 >10 
16b 1.68 1.77 1.24 >10 >10 
16c 2.33 3.45 1.88 >10 >10 
16d 2.56 3.01 1.97 >10 >10 
16e 4.89 4.56 5.89 >10 >10 
16f 4.67 3.99 5.68 >10 >10 
16g 7.54 8.45 >10 >10 >10 
24a 2.15 2.67 2.98 >10 >10 
24b 1.95 1.92 3.29 >10 >10 
24c 1.33 1.45 1.12 >10 >10 
24d 1.28 1.49 1.05 >10 >10 
24e 4.89 5.67 6.97 >10 >10 
24f 4.45 5.09 5.78 >10 >10 
24g 7.12 7.29 8.14 >10 >10 
SAHA 2.42 2.06 2.12 >10 >10 
a  IC50 values were determined using trypan blue exclusion.  Each value is obtained 





4.3.2 Molecular Mechanisms for Macrocyclic HDAC Inhibition 
An important biomarker that is primarily associated with intracellular HDAC 
inhibition is the expression level of the p21waf1 gene.  Upregulation of the p21waf1 gene has 
generally been observed with cellular HDAC inhibition.31,32  In an effort to understand the 
cellular mechanisms contributing to the observed anticancer activity of macrocyclic 
HDACi, we investigated the effect of 24d, a representative macrocyclic HDACi on the 
expression level of p21waf1 protein in SK-MES-1 cells.  SAHA was used as a positive 
control for HDAC inhibition.  Cells were exposed to HDACi for 8 hours and cellular p21waf1 
expression was quantified by immunoblotting.  Results show a dose-dependent increase in 
p21waf1 expression in response to HDACi treatment (Figure 4-8).  This provided additional 
evidence that the likely mechanism of anticancer activity of nonpeptide macrocyclic 
hydroxamates is through intracellular HDAC inhibition. 
 
 
Figure 4-8:  Immunoblot of p21waf1 expression in 
response to macrocyclic HDACi. 
SK-MES-1 cells were dosed for 8 hours with SAHA and 
24d.  Actin expression (green) was used as an indicator of 




4.4 In Vivo Lung Targeting by Macrocyclic HDACi 
The robust HDAC inhibition and anticancer activity observed during in vitro screening of 
nonpeptide macrocyclic HDACi encouraged further progression into in vivo validation as a lung-
targeted HDACi therapeutic.  The 15-membered series of macrocyclic hydroxamates, 
specifically 16a and 16c, were chosen as lead compounds due to the validated lung targeting and 
accumulation properties of the azithromycin macrolide.13-16  Male Balb/C mice were used for 
further screening of compounds that possessed promising tissue distribution profiles.   
 
4.4.1 Maximum Tolerated Dose of Macrocyclic HDACi in Mice 
Since azithromycin accumulates over time in the lungs,33 it is possible that toxicity due to 
increasing in vivo concentrations of 16a and 16c could invalidate any antitumor activity these 
compounds could confer.  To screen for in vivo toxicity, male Balb/C mice were injected 
intravenously with 16a and 16c at concentrations up to 100 mg/kg body mass daily, for five 
days.  SAHA was used as a standard for HDACi activity.  Animals were observed for signs of 
toxicity including loss of more than 10% body mass, hyperactive erratic behavior, difficulty 
moving, seizures, hunching, and squinting.  No signs of stress were observed with either 
compound and all animals survived the five day injection with moderate weight gain (Figure 4-
9).  The lack of observable toxicity for all compounds assuaged concern over the accumulation 







Figure 4-9:  In vivo toxicity caused by macrocyclic HDACi treatment, measured 
by weight loss.  Mice were weighed before injection of macrocyclic HDACi.  
Loss of 10% of age-adjusted mass was taken as an indicator of toxicity/stress that 
would require euthanasia.  Error bars demonstrate 1 standard deviation above or 




4.4.2 Tissue Distribution of Radiolabeled Macrocyclic HDAC Inhibitors 
The extent to which the macrolide cap group conferred in vivo lung-targeting and 
accumulation properties onto nonpeptide macrocyclic HDACi was investigated through a 
radioactive assay that we designed.  Carbon-14 (14C)-labeled analogs of 16a and 16c (17a and 
17c, respectively) were synthesized for a liquid scintillation-based assay to determine the tissue 
distribution of macrocyclic HDACi in the Balb/C mouse model (Figure 4-10).  Isotopically-
labeled 14C-azithromycin was also synthesized for use as a lung-targeted control (Figure 4-11).  
Nonradioactive acetylated 15-membered macrocyclic hydroxamates (Figure 4-12) were also 
synthesized and tested in Balb/C mice as a toxicity control for the acetyl group addition to the 
macrolide scaffold.  A five day dosing regimen of daily intravenous injections of nonradioactive 
acetylated compounds at 100 mg/kg in Balb/C mice caused no discernible toxicity (Figure 4-13).  
DMSO was used as a vehicle control for the acetylated compounds.   
 
 
Figure 4-10:  Radiolabeled 15-membered macrocyclic hydroxamates.  




Figure 4-11:  Compound 18 (14C-azithromycin).  
 
 
Figure 4-12: Acetylated 15-membered hydroxamates.  







Figure 4-13:  Acetylated 15-membered hydroxamates caused no 
discernible toxicity in Balb/C mice over 5 days, dosed intravenously with 
100 mg/kg drug.  Each point is the mean of three mice.  Error bars show 1 





To determine the tissue distribution of radiolabeled macrocyclic HDACi, compounds 17a 
and 17c were injected intravenously into Balb/C mice for 8 hours and 24 hours at a concentration 
of 50 mg/kg.  At the end of each timecourse, animals were sacrificed and relevant tissues and 
blood samples were removed.  Blood samples were centrifuged in serum separator tubes to 
isolate the serum fraction and tissues were rinsed with saline to remove blood.  Equal masses of 
tissues and volumes of serum were solubilized and the radioactive activity present was 
determined via liquid scintillation counting.  The concentrations of radiolabeled macrocyclic 
HDACi present in each sample (Figure 4-14) were determined through comparison to calibration 
curves of each compound (shown in Appendix). 
The resulting tissue distribution showed significant lung-targeting by macrocyclic 
HDACi, with 17c preferentially accumulated in the lungs at both timepoints.  For both 
compounds, lung concentrations remained approximately constant over the course of 8 to 24 
hours (Figure 4-14).  Both compounds also localized to the liver in high concentrations 
comparable to levels in the lungs.  This result trends with literature reports of elevated liver 
concentrations of azithromycin several hours after treatment.34   Biliary excretion through the 
liver is also the primary mode of elimination for azithromycin and mononuclear phagocyte 
system macrophages reside in the liver so it is possible that macrolide-loaded hepatic 
macrophages could account for high levels of liver localization, at least in part.35,36  By contrast, 
levels of macrocyclic HDACi in serum and other tissues were relatively low, consistent with 








Figure 4-14:  Biodistribution of radiolabeled macrocylic hydroxamates in relevant organs 
and blood fractions in Balb/C mice.  Each bar represents the mean of 8 tissue or blood 
fraction samples.  Error bars represent ± 1 standard deviation.  
 
Radiolabeled azithromycin, by contrast, displayed remarkably higher tissue 
concentrations with significant concentrations localized to the lungs, liver, and spleen.  This is 
consistent with the reported pharmacokinetics of unlabeled azithromycin.34  Compared with 
radiolabeled macrocyclic HDACi, 18 localizes to the lungs in slightly higher concentrations that 
decrease somewhat over 16 hours.  Levels of azithromycin in the liver were much higher 
compared to 17a and 17c, but these decreased over 16 hours as well.  The most significant 
difference between the biodistributions of 17a/c and 18 is the 25-fold increase in spleen 
residence of 18.  The spleen is a major organ of the mononuclear phagocyte system and contains 
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high concentrations of splenic macrophages that play roles in innate and aquired immune 
responses which could account for the increase in spleen concentrations.39  Off-target adipose 
and heart tissues have low levels of 18.  This result suggests that attachment of the HDACi 
moiety abrogates, at least in part, the spleen-directed distribution properties of the parent 
macrolide and drastically reduces liver residence.  Lung-targeted concentrations are not 
diminished significantly between 17c, the better of the two radiolabeled macrocyclic HDACi, 
and 18.  The in vivo tissue distribution profile revealed through the liquid scintillation results 
suggest that nonpeptide macrocyclic HDACi could be used to treat lung cancer due to the unique 






Figure 4-15:  Biodistribution of radiolabeled azithromycin in relevant organs and blood 
fractions in Balb/C mice. All bars are the average of 8 tissue or blood fraction samples.  Error 
bars represent one standard deviation above and below the mean.  
 
4.5 Conclusion 
The clinical efficacy of HDACi-based chemotherapies is greatly reduced in solid tumors.  
This shortcoming must be addressed for broader use and success of HDACi therapies.  Targeted 
HDACi with distinct tissue distributions could more selectively concentrate in specific cancer-
burdened tissues, focusing anticancer activity where it is needed and lowering side effects.  The 
macrocyclic-peptide class of HDACi possesses the most complex cap-group moieties and offers 
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the best opportunity for specific modulation of HDACi biological activity.  Replacement of the 
pharmacokinetically disadvantaged cyclic-peptide cap group with azithromycin and 
clarithromycin macrolide skeletons yielded potent nonpeptide macrocyclic HDACi.  A subset of 
these compounds inhibited HeLa nuclear extract HDACs many fold more potently than SAHA 
and had low micromolar anticancer activities against lung cancer and prostate cancer.  Moreover, 
nonpeptide macrocyclic HDACi caused no observable in vitro toxicity in normal human cells or 
in an animal model dosed for five days with a concentration of 100 mg/kg/day.  Most 
importantly, azithromycin-based macrocyclic HDACi display a tissue distribution profile that 
mimics the parent macrolide, and targets the compounds selectively to lung and liver tissues, 
consistent with recorded pharmacokinetic profiles.  These nonpeptide macrocyclic HDACi 
display great promise in overcoming the inefficacy of HDACi in treating solid tumors, 
harnessing lung-targeting conferred by the appended macrolide and potent anti-HDAC and 
anticancer activity. 
The future direction of this project must center on challenging an in vivo lung tumor with 
these HDACi and evaluating their efficacy in order to validate that tissue-targeted HDACi can 
surpass the limitations that current agents have shown in the clinic.  Ideally, an animal model that 
can be implanted with a lung tumor that can be detected and evaluated for growth inhibition will 
be used.  It is essential that an orthotopic tumor implant be used to test the efficacy of nonpeptide 
macrocyclic HDACi, rather than a heterotopic tumor.  The unique pharmacokinetic/delivery 
properties conferred on these compounds by the azithromycin skeleton may be dependent on 
lung-associated macrophages or other phagocytic cells.33  Lewis lung carcinoma (LLC), a mouse 
lung cancer cell line has been chosen for initial in vivo anticancer activity experiments.  This cell 
line has demonstrated in vivo responses to TSA treatment40 and has been commonly used for 
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anticancer agent profiling.41-43 Most importantly, LLC is significantly inhibited by 16c in low 
micromolar concentrations ( IC50 = 1.1 µM)(Figure 4-16). 
 
 
Figure 4-16:  HDACi-induced decrease in LLC Viability. LLC cells were dosed for 72 hours 
with 16c.  Viability was determined using the MTS assay. 
 
Two imaging strategies have been designed to facilitate observation of the tumor within a 
live mouse: (a) a stably-transfected luciferase-expressing LLC line for luminescent bioimaging, 
and (b) labeling of epidermal growth factor receptor (EGFR) on LLC with a near-infrared (NIR) 
probe for fluorescent imaging.  The luciferase activity of the transfected LLC line correlates well 
with cell number when compared directly with MTS results (data not shown).  Alternatively, the 
near-infrared probe has shown suitability in labeling these cells in vitro for the same end purpose 
(Figure 4-17).  The resulting in vivo anti-lung cancer activity will determine the ultimate legacy 
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of these compounds, but one would think the successes shown so far will stimulate further 
investigation and design of tissue-targeted HDAC therapies.  
 
 1           2            3           4           5           6 
 
Figure 4-17:  On-cell western blot of EGFR on LLC with a NIR probe. 
Wells:  1) Control, 2) 1 ng/ml, 3) 10 ng/ml, 4) 100 ng/ml, 5) 250 ng/ml, 
6) 500 ng/ml.  Cells were labeled with the 800CW-EGF 
NIR probe (LiCor) according to manufacturer’s protocol. 
 
 
4.6 Experimental Methods 
4.6.1  In Vitro HDAC Inhibition 
In vitro HDAC inhibition was assayed using the HDAC Fluorimetric Assay/Drug 
Discovery Kit.  15 µL of HeLa nuclear extract was mixed with 5 µL of 10× compound and 5 µL 
of assay buffer.  Fluorogenic substrate (25 µL) was added, and reaction was allowed to proceed 
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for 15 min at room temperature and then stopped by addition of a developer containing TSA.  
Fluorescence was monitored after 15 min at excitation and emission wavelengths of 360 and 460 
nm, respectively. IC50 values were determined using logit plots. 
4.6.2 Cancer Cell Cytotoxicity 
DU-145 prostate carcinoma, SK-MES-1 non-small cell lung carcinoma, and NCI-H69 
small cell lung carcinoma were obtained from ATCC (Manassass, VA) and maintained in the 
recommended growth mediums.  All cell lines were maintained in a 37°C incubator with a 5% 
CO2 environment.  All compounds to be tested were dissolved to a concentration of 10 mM in 
DMSO and stored at -80°C.  Cells were passaged 24 h prior to cell viability experiments.  For 
cancer cell viability experiments, cells were dosed for 72 h and viability was determined both by 
Trypan Blue staining and through the use of the MTS assay (Promega) according to 
manufacturer’s instructions.  Control wells were dosed with fresh media containing 0.1% 
DMSO. 
4.6.3 Immunoblotting of p21
waf1
 
SK-MES-1 lung cancer cells were passaged 24 h prior to the experiment.  Compounds to 
be tested were diluted in the growth medium so that the final concentration of DMSO was 0.1% 
and control cells were dosed with fresh media containing 0.1% DMSO.  Cells were dosed for 8 
h, then washed twice with ice-cold PBS, and lysed on the culture plate at 4°C for 5 min with 
RIPA buffer containing protease inhibitors.  Lysates were mixed repeatedly by pipetting and 
centrifuged at 14,000 X g for 15 minutes at 4°C.  Supernatant was saved and protein 
concentration was quantified using the Bio-Rad Protein Assay (Bio-Rad) with BSA as the 
standard.  Loading buffer was added and protein samples were incubated at 100°C for 10 min 
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before electrophoresis.  Proteins were then transferred to a nitrocellulose membrane for 1 h, 
followed by blocking overnight in a 1:1 mixture of Odyssey Blocking Buffer (LiCor 
Biosciences) and PBS.  Membranes were incubated with primary antibodies, washed with 0.1% 
Tween-20 in PBS four times for 5 minutes each, and then incubated with secondary antibodies, 
followed by another four washing steps.   Both sets of antibodies were diluted in 1:1 Odyssey 
Blocking Buffer/PBS.  Membranes were scanned on the Odyssey infrared imaging system 
(LiCor Biosciences) using both 700 nm and 800 nm channels simultaneously at 169 µm 
resolution and analyzed on the imaging software. 
4.6.4 In Vivo Lung Targeting 
All Balb/C mice were obtained from Jackson Laboratories and housed according to 
protocol in the PRL.  During experiments involving injections of HDACi, animals were observed 
at least twice daily for sign of distress that would require immediate euthanasia.  All experiments 
were carried out using strict aseptic technique. 
For jugular vein injections, used to intravenously inject HDACi or radiolabeled 
compounds, mice were prepared one day prior to the experiment by removing the hair from the 
neck to the lower rib line with a depilatory cream.  On the day of the experiment, mice were 
anesthetized with 2-2.5% isoflurane such that no semiconscious response was elicited with toe 
pinching.  Mice were laid in the dorsal decubitus position on a heating pad to maintain body 
temperature.  The upper chest was elevated by placing a cotton swab under the mouse’s mid-
back.  Compounds in DMSO were injected, in no more than 20µl total volume, through the 
pectoral muscle into the jugular vein.  The syringe was then slowly removed and light pressure 
was applied to the chest for up to 1 minute to facilitate clotting at the injection site.  Mice were 
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removed from anesthesia and allowed to wake on the warming pad before being placed back in 
their cages.  Animals were observed for several minutes for signs of distress or injection site 
irritation.  Animals that presented significant signs of distress were immediately euthanized by 
carbon dioxide asphyxiation.  Euthanasia was not necessary for any of the animals in the 
described experiments as none showed significant signs of distress that would warrant 
termination.  Animals were weighed before all injections. 
For radiological tissue distribution experiments, a protocol approved by the Georgia Tech 
Office of Radiological Safety was followed.  Mice were kept in static isolator cages with no 
bedding, water, or food, in order to minimize the spread of radioactive material.  Slices of Napa 
Nectar (Lenderking), a gel-based water source were placed in the cage.  All cages were retrieved 
before the experiment started and all cages remained in the experiment room for the duration of 
the timecourse.  At the appropriate timepoints, animals were sacrificed by isoflurane inhalation 
overdose.  The heart was quickly punctured and blood was removed and placed in serum isolator 
tubes.  A general incision was then made to the abdomen of the animal.  Liver, spleen, and 
adipose were removed and placed in microtubes on ice.  The heart and lungs were then removed 
and skeletal muscle was collected from the flank and placed in microtubes.  All samples were 
washed with PBS to remove blood and then quickly frozen in an acetone/dry ice mixture and 
stored. 
Equal masses of samples from each tissue type and equal volumes of serum (55 mg of 
tissues, 55 µl of serum samples) were collected and solubilized using a commercially available 
aqueous tissue solubilizer (SOLVABLE, Perkin Elmer) in glass scintillation vials.  Samples and 
solubilizer were heated to 60°C with shaking for at least 4 hours each.  After the samples were 
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completely dissolved, a 30% hydrogen peroxide solution was added to all samples to bleach the 
pigments released by the tissues.  This solution was further heated for 20 minutes before being 
allowed to cool on the bench top.  After the solutions were cooled, scintillation fluid (Ultima 
Gold, Perkin Elmer) was added to the biological solutions, swirled, and allowed to sit at room 
temperature for 15 minutes.  Vials were then counted using the Packard TriCarb 2900TR 
Scintillation Counter set to 14C counts.  Masses of drug within tissues were calculated based off a 
calibration curve generated for each compound. 
4.6.5  Stable Transfection of LLC cells with luciferase gene plasmid. 
LLC cells were obtained from ATCC and maintained in OPTI-MEM (Invitrogen) prior to 
transfection.  The pGL4.50 vector was obtained from Promega.  This vector contains a luciferase 
gene under control of a high expression promoter, with a hygromycin resistance gene for 
selection of stably transfected cells.  Prior to transfection, a kill curve experiment was performed 
to determine the optimal concentration of hygromycin to use for selection.  The Lipofectamine 
2000 Transfection Reagent (Invitrogen) was used according to the manufacturer’s directions and 
cells were maintained in hygromycin-containing media for 3 weeks with passaging as needed 
before testing for luciferase expression.  The Luciferase Assay System (Promega) was used to 
test for luciferase activity. 
4.6.6  On cell western blot of EGFR with NIR probe 
LLC cells were seeded with a density of 1 x 105 cells/ml in complete Opti-Mem media in 
a 96-well tissue culture plate and allowed to grow for 24 hours.  Media was then removed and 
serum-free Opti-Mem was added and incubated at 37°C for a duration of 4 hours.  All 
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subsequent steps were performed at room temperature and shielded from light as much as 
possible.  Dilutions of the probe were made in Opti-Mem with concentrations ranging from 1 to 
500 ng/ml, and then added after serum-free media had been aspirated. After two minutes, the 
media was removed and the cells were fixed with 3.7% formaldehyde in PBS for 20 minutes.  
Cells were then washed 5 times for 5 minutes each with a Tween-based wash buffer (0.1% 
Tween-20 in PBS).  After the last wash, the buffer was removed and the microplate was inverted 
and tapped gently on a paper towel to remove excess buffer.  The plate was then scanned at both 
700 and 800 nm channels on the Odyssey imaging system (LiCor). 
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Examples of Inhibition Graphs and Logit Analysis for Determining HDAC or anticancer IC50’s. 
Concentration (nM) Fluorescence Control 
% 
Inhibition log(conc.) logit(fluor) 4b  
0 410.15 410.15 100.00 1.40 0.55   
25 319.17  77.82 1.70 0.26   
50 264.43  64.47 2.00 0.02   
100 210.31  51.28 2.40 -0.28   
250 140.95  34.37 2.70 -0.54   
500 91.67  22.35 3.00 -0.76   
1000 60.99  14.87     
 
         
        
        
        
        
        
        
        
        
        
        
        
Control 25 50 100 250 500 1000  
423.258 275.265 268.347 218.325 145.53 90.56 57.163  
410.258 340.007 307.063 199.304 146.568 94.552 66.854  
396.94 342.229 217.885 213.293 130.76 89.904 58.965  
 
         
        
        
        
        
        
        
     IC50 (nM)   
     110.50   
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Concentration (nM) Fluroescence Control % Inhibition log(conc) logit(fluor) 7y 
0 366.47 366.47 100.00 1.40 1.23  
25 345.91  94.39 1.70 0.78  
50 314.48  85.81 2.00 0.54  
100 283.87  77.46 2.40 0.53  
250 283.49  77.36 2.70 0.34  
500 251.21  68.55 3.00 0.52  
1000 281.40  76.79    
 
        
       
       
       
       
       
       
       
       
       
       
       
Control 25 50 100 250 500 1000 
375.029 315.258 328.158 285.111 337.056 248.212 279.264 
344.155 378.216 301.162 304.745 268.956 214.763 284.642 
380.215 344.256 314.108 261.746 244.452 290.666 280.303 
       
       
 
        
       
      
IC50 (nM) 
N.D. 
       
       
       




       
Calibration Curve for Radiolabeled compound 17a. 
Concentration (mg/ml) DPM       
0.25 15507       
0.1 6152       
0.05 3264       
0.025 1477       
0.01 593       
0.001 244       
        
        
 
         
        
        
        
        
        
        
        
        
        
        
        
        
        
        




Calibration curve for radiolabeled compound 17c. 
Concentration (mg/ml) DPM      
0.25 16024      
0.1 6233      
0.05 3109      
0.025 1542      
0.01 609      
0.001 275      
       
       
 
        
       
       
       
       
       
       
       
       
       
       
       
       
       




William Guerrant was born in Thomson, Georgia.  He attended public schools in 
Thomson, Georgia and received a B.S. in Biochemistry and Molecular Biology from the 
University of Georgia, Athens, GA in 2005 before coming to Georgia Tech to pursue a doctorate 
in Chemistry.  When he is not working on his research, William enjoys spending time with his 
friends, playing soccer, and exercising. 
